Document_and_Entity_Informatio
Document and Entity Information (USD $) | 12 Months Ended | ||
In Millions, except Share data, unless otherwise specified | Dec. 31, 2013 | Mar. 24, 2014 | Jun. 28, 2013 |
Document And Entity Information [Abstract] | ' | ' | ' |
Document Type | '10-K | ' | ' |
Amendment Flag | 'false | ' | ' |
Document Period End Date | 31-Dec-13 | ' | ' |
Document Fiscal Year Focus | '2013 | ' | ' |
Document Fiscal Period Focus | 'FY | ' | ' |
Entity Registrant Name | 'Mast Therapeutics, Inc. | ' | ' |
Entity Central Index Key | '0001160308 | ' | ' |
Current Fiscal Year End Date | '--12-31 | ' | ' |
Entity Well-known Seasoned Issuer | 'No | ' | ' |
Entity Current Reporting Status | 'Yes | ' | ' |
Entity Voluntary Filers | 'No | ' | ' |
Entity Filer Category | 'Smaller Reporting Company | ' | ' |
Entity Common Stock, Shares Outstanding | ' | 113,607,834 | ' |
Entity Public Float | ' | ' | $44 |
Consolidated_Balance_Sheets
Consolidated Balance Sheets (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
Current assets: | ' | ' |
Cash and cash equivalents | $25,681,092 | $22,500,440 |
Investment securities | 18,711,448 | 14,010,962 |
Prepaid expenses and other current assets | 1,135,490 | 662,260 |
Total current assets | 45,528,030 | 37,173,662 |
Property and equipment, net | 105,747 | 198,358 |
In-process research and development | 6,549,000 | 6,549,000 |
Goodwill | 3,006,883 | 3,006,883 |
Other assets | 60,312 | 43,912 |
Total assets | 55,249,972 | 46,971,815 |
Current liabilities: | ' | ' |
Accounts payable | 963,947 | 698,838 |
Accrued liabilities | 2,495,088 | 1,283,976 |
Accrued compensation and payroll taxes | 1,374,343 | 445,352 |
Contingent liability | ' | 142,500 |
Total current liabilities | 4,833,378 | 2,570,666 |
Deferred income tax liability | 2,608,755 | 2,608,755 |
Total liabilities | 7,442,133 | 5,179,421 |
Commitments (Note 10) | ' | ' |
Stockholders' equity: | ' | ' |
Common stock, $0.001 par value; 500,000,000 shares authorized; 102,710,286 and 47,719,365 shares issued at December 31, 2013 and 2012, respectively; 102,710,286 and 46,265,286 shares outstanding at December 31, 2013 and 2012, respectively | 102,710 | 47,720 |
Treasury stock, at cost - 1,454,079 shares at December 31, 2012 | ' | -1,454 |
Additional paid-in capital | 254,154,693 | 226,696,863 |
Accumulated other comprehensive loss | -20,738 | -2,194 |
Deficit accumulated during the development stage | -206,428,826 | -184,948,541 |
Total stockholders' equity | 47,807,839 | 41,792,394 |
Total liabilities and stockholders' equity | $55,249,972 | $46,971,815 |
Consolidated_Balance_Sheets_Pa
Consolidated Balance Sheets (Parenthetical) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
Statement Of Financial Position [Abstract] | ' | ' |
Common stock, par value | $0.00 | $0.00 |
Common stock, shares authorized | 500,000,000 | 500,000,000 |
Common stock, shares issued | 102,710,286 | 47,719,365 |
Common stock, shares outstanding | 102,710,286 | 46,265,286 |
Treasury stock, shares | ' | 1,454,079 |
Consolidated_Statements_of_Ope
Consolidated Statements of Operations and Comprehensive Income/ (Loss) (USD $) | 12 Months Ended | 211 Months Ended | |
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | |
Revenues: | ' | ' | ' |
Net sales | ' | ' | $174,830 |
Licensing revenue | ' | ' | 1,300,000 |
Grant revenue | ' | ' | 618,692 |
Total net revenue | ' | ' | 2,093,522 |
Cost of goods sold | ' | ' | 51,094 |
Gross margin | ' | ' | 2,042,428 |
Operating expenses: | ' | ' | ' |
Research and development | 12,902,263 | 8,088,152 | 98,959,719 |
Selling, general and administrative | 8,517,781 | 7,519,405 | 76,184,493 |
Transaction-related expenses | 79,640 | -69,602 | 751,292 |
Depreciation and amortization | 39,517 | 90,047 | 11,064,752 |
Write-off of in-process research and development | ' | ' | 10,422,130 |
Goodwill impairment | ' | ' | 5,702,130 |
Equity in loss of investee | ' | ' | 178,936 |
Total operating expenses | 21,539,201 | 15,628,002 | 203,263,452 |
Loss from operations | -21,539,201 | -15,628,002 | -201,221,024 |
Reduction of fair value of warrants | ' | ' | -12,239,688 |
Interest income | 60,268 | 73,560 | 4,892,476 |
Interest expense | ' | ' | -191,729 |
Other income (expense), net | -1,352 | -5,047 | 128,353 |
Loss before cumulative effect of change in accounting principle | -21,480,285 | -15,559,489 | -208,631,612 |
Cumulative effect of change in accounting principle | ' | ' | -25,821 |
Net loss | -21,480,285 | -15,559,489 | -208,657,433 |
Preferred stock dividends | ' | ' | -621,240 |
Deemed dividends on preferred stock | ' | ' | -10,506,683 |
Net loss applicable to common stock | -21,480,285 | -15,559,489 | -219,785,356 |
Loss per common share - basic and diluted | ($0.28) | ($0.33) | ' |
Weighted average shares outstanding - basic and diluted | 76,585,752 | 47,641,043 | ' |
Comprehensive Income/(Loss): | ' | ' | ' |
Net loss | -21,480,285 | -15,559,489 | -208,657,433 |
Unrealized gains (losses) on marketable securities | -18,544 | 104 | -18,582 |
Foreign currency translation adjustments | ' | ' | -2,156 |
Comprehensive net loss | ($21,498,829) | ($15,559,385) | ($208,678,171) |
Consolidated_Statements_of_Sto
Consolidated Statements of Stockholders' Equity (Deficit) (USD $) | Total | Series A [Member] | Series D | Series A Preferred Stock [Member] | Series B Preferred Stock [Member] | Common Stock Selling Price at $2.75 [Member] | Series C Preferred Stock [Member] | Series D Preferred Stock [Member] | Series E Preferred Stock [Member] | Series F Preferred Stock [Member] | Cumulative Convertible Preferred Stock, Series A Through C [Member] | Cumulative Convertible Preferred Stock, Series A Through C [Member] | Cumulative Convertible Preferred Stock, Series A Through C [Member] | Convertible Preferred Stock, Series A (2009) [Member] | Convertible Preferred Stock, Series A (2009) [Member] | Cumulative Convertible Preferred Stock, Series B Through F (2009-2010) [Member] | Cumulative Convertible Preferred Stock, Series B Through F (2009-2010) [Member] | Cumulative Convertible Preferred Stock, Series B Through F (2009-2010) [Member] | Cumulative Convertible Preferred Stock, Series B Through F (2009-2010) [Member] | Cumulative Convertible Preferred Stock, Series B Through F (2009-2010) [Member] | Cumulative Convertible Preferred Stock, Series B Through F (2009-2010) [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | Accumulated Other Comprehensive Income (Loss) [Member] | Deficit Accumulated During Development Stage [Member] | Deficit Accumulated During Development Stage [Member] | Deficit Accumulated During Development Stage [Member] | Deficit Accumulated During Development Stage [Member] | Deficit Accumulated During Development Stage [Member] | Deficit Accumulated During Development Stage [Member] | Deficit Accumulated During Development Stage [Member] | Treasury Stock, at Cost [Member] |
Series A Preferred Stock [Member] | Series B Preferred Stock [Member] | Series A Preferred Stock [Member] | Series B Preferred Stock [Member] | Series C Preferred Stock [Member] | Series D Preferred Stock [Member] | Series E Preferred Stock [Member] | Series F Preferred Stock [Member] | Series A [Member] | Series D | Series A Preferred Stock [Member] | Series B Preferred Stock [Member] | Common Stock Selling Price at $2.75 [Member] | Series C Preferred Stock [Member] | Series D Preferred Stock [Member] | Series E Preferred Stock [Member] | Series F Preferred Stock [Member] | Series A [Member] | Series D | Series A Preferred Stock [Member] | Series B Preferred Stock [Member] | Common Stock Selling Price at $2.75 [Member] | Series C Preferred Stock [Member] | Series D Preferred Stock [Member] | Series E Preferred Stock [Member] | Series F Preferred Stock [Member] | Series A Preferred Stock [Member] | Series B Preferred Stock [Member] | Series C Preferred Stock [Member] | Series D Preferred Stock [Member] | Series E Preferred Stock [Member] | Series F Preferred Stock [Member] | |||||||||||||||||||
Beginning balances at Jun. 11, 1996 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Beginning balances, shares at Jun. 11, 1996 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Sale of common stock without par value | 10 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 10 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Sale of common stock without par value, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 20 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock in acquisition | -13,154 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 69 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4,871 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -18,094 | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock in acquisition, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 68,645 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Sale of common/preferred stock | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 80 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,386 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -2,466 | ' | ' | ' | ' | ' | ' | ' |
Sale of common/preferred stock, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 80,405 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | -259,476 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -259,476 | ' | ' | ' | ' | ' | ' | ' |
Ending balances at Dec. 31, 1996 | -272,620 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 149 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 7,267 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -280,036 | ' | ' | ' | ' | ' | ' | ' |
Ending balances, shares at Dec. 31, 1996 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 149,070 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Sale of common stock, net of offering costs | 1,790,979 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 40 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,790,939 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Sale of common stock, net of offering costs, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 40,182 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Minority interest deficiency at acquisition charged to the Company | -45,003 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -45,003 | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock in acquisition | 888,250 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 15 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 888,235 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock in acquisition, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 15,036 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | -1,979,400 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -1,979,400 | ' | ' | ' | ' | ' | ' | ' |
Ending balances at Dec. 31, 1997 | 382,206 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 204 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,686,441 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -2,304,439 | ' | ' | ' | ' | ' | ' | ' |
Ending balances, shares at Dec. 31, 1997 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 204,288 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Rescission of acquisition | -327,084 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -15 | ' | ' | ' | ' | ' | ' | ' | ' | ' | -888,235 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 561,166 | ' | ' | ' | ' | ' | ' | ' |
Rescission of acquisition, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -15,036 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock at conversion of notes and interest payable | 364,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 18 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 363,982 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock at conversion of notes and interest payable, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 18,011 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Expense related to stock warrants issued / Detachable warrants issued with notes payable / Issuance of warrants in settlement of a claim | 260,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 260,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | -1,204,380 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -1,204,380 | ' | ' | ' | ' | ' | ' | ' |
Ending balances at Dec. 31, 1998 | -525,258 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 207 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,422,188 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -2,947,653 | ' | ' | ' | ' | ' | ' | ' |
Ending balances, shares at Dec. 31, 1998 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 207,263 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Sale of common stock without par value | 135,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 27 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 134,973 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Sale of common stock without par value, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 27,136 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Expense related to stock warrants issued / Detachable warrants issued with notes payable / Issuance of warrants in settlement of a claim | 212,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 212,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | -1,055,485 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -1,055,485 | ' | ' | ' | ' | ' | ' | ' |
Ending balances at Dec. 31, 1999 | -1,233,743 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 234 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,769,161 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -4,003,138 | ' | ' | ' | ' | ' | ' | ' |
Ending balances, shares at Dec. 31, 1999 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 234,399 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Dividends payable on preferred stock | -85,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -85,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Sale of preferred stock value, net offering costs | 3,123,500 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 32 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,123,468 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Sale of preferred stock shares, net offering costs, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,200 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock at conversion of notes and interest payable | 492,497 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 16 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 492,481 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cashless exercise of warrants | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 24 | ' | ' | ' | ' | ' | ' | ' | ' | ' | -24 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock at conversion of notes and interest payable, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 16,499 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cashless exercise of warrants, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 23,963 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock to settle obligations / Issuance of common stock to pay interest on Bridge Notes | 1,202,160 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 20 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,202,140 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock to settle obligations / Issuance of common stock to pay interest on Bridge Notes, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 19,804 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of warrants for acquisition | 4,767,664 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4,767,664 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock issued for acquisition costs | 487,500 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 6 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 487,494 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock in acquisition | 9,332,769 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 280 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 9,332,489 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock issued for acquisition costs, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 6,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock in acquisition, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 280,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Expense related to stock warrants issued | 140,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 140,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock at conversion of notes payable / Conversion of preferred stock into common stock / Conversion of Series C preferred stock into common stock | 84,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 83,997 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock at conversion of notes payable / Conversion of preferred stock into common stock / Conversion of Series C preferred stock into common stock, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,814 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | -3,701,084 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -3,701,084 | ' | ' | ' | ' | ' | ' | ' |
Ending balances at Dec. 31, 2000 | 14,610,263 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 32 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 583 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 22,313,870 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -7,704,222 | ' | ' | ' | ' | ' | ' | ' |
Ending balances, shares at Dec. 31, 2000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,200 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 583,479 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Dividends payable on preferred stock | -256,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -256,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Repurchase of warrants | -55,279 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -55,279 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Sale of warrants | 47,741 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 47,741 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cashless exercise of warrants | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 9 | ' | ' | ' | ' | ' | ' | ' | ' | ' | -9 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock to pay preferred dividends | 213,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 212,996 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cashless exercise of warrants, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 8,740 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock to pay preferred dividends, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,737 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Expense related to stock warrants issued / Detachable warrants issued with notes payable / Issuance of warrants in settlement of a claim | 450,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 450,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of warrants to pay operating expenses | 167,138 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 167,138 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of preferred stock to pay operating expenses | 136,500 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 136,499 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of preferred stock to pay operating expenses, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 137 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock to pay operating expenses | 387,271 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 387,267 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock to pay operating expenses, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4,252 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | -16,339,120 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -16,339,120 | ' | ' | ' | ' | ' | ' | ' |
Ending balances at Dec. 31, 2001 | -638,486 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 33 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 600 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 23,404,223 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -24,043,342 | ' | ' | ' | ' | ' | ' | ' |
Ending balances, shares at Dec. 31, 2001 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,337 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 600,208 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Dividends payable on preferred stock | -242,400 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -242,400 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Sale of warrants | 117,853 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 10 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 117,843 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Sale of warrants, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 9,600 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cashless exercise of warrants | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4 | ' | ' | ' | ' | ' | ' | ' | ' | ' | -4 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cashless exercise of warrants, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4,008 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Exercise of warrants | 168,822 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 14 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 168,808 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Exercise of warrants, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 13,783 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Sale of preferred stock | 701,093 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 701 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 700,392 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Sale of preferred stock, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 70,109 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Sale of common/preferred stock | 300,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 298,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Preferred stock dividends forgiven | 335,440 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 335,440 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Sale of common/preferred stock, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 200,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock at conversion of notes payable / Conversion of preferred stock into common stock / Conversion of Series C preferred stock into common stock | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -30 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 72 | ' | ' | ' | ' | ' | ' | ' | ' | ' | -42 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock at conversion of notes payable / Conversion of preferred stock into common stock / Conversion of Series C preferred stock into common stock, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -3,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 72,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of warrants to pay operating expenses | 163,109 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 163,109 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of preferred stock to pay operating expenses | 6,001 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 6,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of preferred stock to pay operating expenses, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 136 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock to pay operating expenses | 12,269 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 12,269 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock to pay operating expenses, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 251 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based compensation expense - employee options | 329,296 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 329,296 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | -2,105,727 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -2,105,727 | ' | ' | ' | ' | ' | ' | ' |
Ending balances at Dec. 31, 2002 | -852,730 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,705 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 700 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 25,292,934 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -26,149,069 | ' | ' | ' | ' | ' | ' | ' |
Ending balances, shares at Dec. 31, 2002 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 270,582 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 699,850 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Dividends payable on preferred stock | -37,840 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -37,840 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock to settle obligations / Issuance of common stock to pay interest on Bridge Notes | 53,491 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 7 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 53,484 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock to settle obligations / Issuance of common stock to pay interest on Bridge Notes, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 6,633 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Exchange of warrants | 49,721 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 9 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 49,712 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Exchange of warrants, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 9,412 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Sale of common stock, net of issuance costs | 3,992,849 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 148 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,992,701 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Sale of common/preferred stock | 2,597,332 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 266 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,597,066 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Sale of common stock, net of issuance costs, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 148,069 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Sale of common/preferred stock, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 265,630 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock at conversion of notes payable / Conversion of preferred stock into common stock / Conversion of Series C preferred stock into common stock | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -701 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 561 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 140 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock at conversion of notes payable / Conversion of preferred stock into common stock / Conversion of Series C preferred stock into common stock, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -70,109 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 560,874 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of warrants to pay operating expenses | 156,735 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 156,735 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock to pay operating expenses | 206,799 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 9 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 206,790 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock to pay operating expenses, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 9,200 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based compensation expense - employee options | 286,033 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 286,033 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | -2,332,077 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -2,332,077 | ' | ' | ' | ' | ' | ' | ' |
Ending balances at Dec. 31, 2003 | 4,120,313 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,004 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,700 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 32,597,755 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -28,481,146 | ' | ' | ' | ' | ' | ' | ' |
Ending balances, shares at Dec. 31, 2003 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 200,473 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,699,668 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Extinguishment of dividends payable on preferred stock | 72,800 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 72,800 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock at conversion of notes and interest payable | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -4 | -2,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 9 | 8 | ' | ' | ' | ' | ' | ' | ' | ' | -5 | 1,992 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cashless exercise of warrants | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 18 | ' | ' | ' | ' | ' | ' | ' | ' | ' | -18 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock at conversion of notes and interest payable, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -473 | -200,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 9,460 | 8,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cashless exercise of warrants, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 18,583 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Exercise of warrants | 27,353 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 27,352 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Exercise of warrants, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 953 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Payment of financing and offering costs | -1,366,774 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -1,366,774 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Acquisition of treasury stock | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 34,747 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -34,747 |
Sale of common stock, net of issuance costs | 15,626,450 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 417 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 15,626,033 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Sale of common stock, net of issuance costs, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 416,705 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Expense related to stock warrants issued / Detachable warrants issued with notes payable / Issuance of warrants in settlement of a claim | 86,375 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 86,375 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based compensation expense - employee options | 524,922 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 524,922 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | -6,701,048 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -6,701,048 | ' | ' | ' | ' | ' | ' | ' |
Ending balances at Dec. 31, 2004 | 12,390,391 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,153 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 47,605,179 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -35,182,194 | ' | ' | ' | ' | ' | ' | -34,747 |
Ending balances, shares at Dec. 31, 2004 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,153,369 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Other comprehensive income/(loss) | -1,722 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -1,722 | ' | ' | ' | ' | ' | ' | ' | ' |
Par value of shares issued in conjunction with mezzanine financing | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 433 | ' | ' | ' | ' | ' | ' | ' | ' | ' | -433 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Par value of shares issued in conjunction with mezzanine financing, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 432,432 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cashless exercise of warrants | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 6 | ' | ' | ' | ' | ' | ' | ' | ' | ' | -6 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cashless exercise of warrants, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 5,985 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Exercise of warrants | 3,073,438 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 90 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,073,348 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Exercise of warrants, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 90,348 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock to vendor | 258,500 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 5 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 258,495 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock to vendor, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 5,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Exercise of stock options | 145,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 7 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 144,993 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Exercise of stock options, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 7,400 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based compensation expense-non-employee options | 93,549 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 93,549 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based compensation expense - employee options | 994,874 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 994,874 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | -24,782,646 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -24,782,646 | ' | ' | ' | ' | ' | ' | ' |
Ending balances at Dec. 31, 2005 | -7,828,616 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,694 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 52,169,999 | ' | ' | ' | ' | ' | ' | ' | ' | ' | -1,722 | -59,964,840 | ' | ' | ' | ' | ' | ' | -34,747 |
Ending balances, shares at Dec. 31, 2005 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,694,534 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Sale of common stock, net of offering costs | ' | ' | ' | ' | ' | 37,070,211 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 582 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 37,069,629 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Other comprehensive income/(loss) | -368 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -368 | ' | ' | ' | ' | ' | ' | ' | ' |
Sale of common stock, net of offering costs, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 581,800 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Exercise of warrants, net of financing costs | 7,691,590 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 204 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 7,691,386 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cashless exercise of warrants | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 17 | ' | ' | ' | ' | ' | ' | ' | ' | ' | -17 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Exercise of warrants, net of financing costs, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 204,150 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cashless exercise of warrants, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 16,807 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of stock for severance agreement | 196,674 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 196,672 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of stock for severance agreement, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,406 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock in acquisition | 10,163,952 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 84 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 10,163,868 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based compensation expense - non-employee restricted stock | 68,650 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 68,649 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock in acquisition, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 84,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based compensation expense - non-employee restricted stock, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 600 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Exercise of stock options | 125,751 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 125,747 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Exercise of stock options, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,700 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cancellation of treasury stock shares/Elimination of treasury stock in connection with offering | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -1 | ' | ' | ' | ' | ' | ' | ' | ' | ' | -34,746 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 34,747 |
Cancellation of treasury stock shares/Elimination of treasury stock in connection with offering, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -927 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based compensation expense-non-employee options | 104,225 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 104,225 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based compensation expense - employee options | 1,697,452 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,697,452 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | -29,331,773 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -29,331,773 | ' | ' | ' | ' | ' | ' | ' |
Ending balances at Dec. 31, 2006 | 19,957,748 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,587 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 109,252,864 | ' | ' | ' | ' | ' | ' | ' | ' | ' | -2,090 | -89,296,613 | ' | ' | ' | ' | ' | ' | ' |
Ending balances, shares at Dec. 31, 2006 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,587,070 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cumulative effect of change in accounting principle | 30,356,439 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 18,116,751 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 12,239,688 | ' | ' | ' | ' | ' | ' | ' |
Other comprehensive income/(loss) | 4,792 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4,792 | ' | ' | ' | ' | ' | ' | ' | ' |
Exercise of stock options | 441,616 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 23 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 441,593 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Exercise of stock options, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 23,033 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based compensation expense-non-employee options | 1,908 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,908 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based compensation expense - employee options | 2,414,077 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,414,077 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | -22,142,040 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -22,142,040 | ' | ' | ' | ' | ' | ' | ' |
Ending balances at Dec. 31, 2007 | 31,034,540 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,610 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 130,227,193 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,702 | -99,198,965 | ' | ' | ' | ' | ' | ' | ' |
Ending balances, shares at Dec. 31, 2007 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,610,103 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Other comprehensive income/(loss) | -2,702 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -2,702 | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based compensation expense-non-employee options | 4,982 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4,982 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based compensation expense - employee options | 1,605,908 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,605,908 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | -26,647,493 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -26,647,493 | ' | ' | ' | ' | ' | ' | ' |
Ending balances at Dec. 31, 2008 | 5,995,235 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,610 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 131,838,083 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -125,846,458 | ' | ' | ' | ' | ' | ' | ' |
Ending balances, shares at Dec. 31, 2008 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,610,103 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Sale of preferred stock value, net offering costs | ' | ' | ' | 1,735,629 | 833,031 | ' | 711,199 | 5,124,136 | ' | ' | ' | ' | ' | ' | 2 | ' | 1 | 1 | 11 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,735,627 | 833,030 | ' | 711,198 | 5,124,125 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Sale of preferred stock shares, net offering costs, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,993 | ' | ' | 1,361 | 922 | 11,283 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Deemed dividend on series A, B, C, D, E, F preferred stock | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,207,536 | 214,795 | ' | 186,173 | 3,258,383 | ' | ' | ' | ' | -1,207,536 | -214,795 | -186,173 | -3,258,383 | ' | ' | ' |
Exercise of warrants | ' | 900,000 | 2,113,920 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 240 | 576 | ' | ' | ' | ' | ' | ' | ' | ' | 899,760 | 2,113,344 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Exercise of warrants, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 240,000 | 576,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock at conversion of notes payable / Conversion of preferred stock into common stock / Conversion of Series C preferred stock into common stock | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -2 | ' | -1 | -1 | -11 | ' | ' | ' | ' | ' | 721 | 380 | ' | 284 | 2,400 | ' | ' | ' | ' | ' | -719 | -379 | ' | -283 | -2,389 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock at conversion of notes payable / Conversion of preferred stock into common stock / Conversion of Series C preferred stock into common stock, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -1,993 | ' | -1,361 | -922 | -11,283 | ' | ' | ' | ' | ' | 721,448 | 380,168 | ' | 283,692 | 2,400,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based compensation expense - employee options | 585,438 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 585,438 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | -11,325,058 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -11,325,058 | ' | ' | ' | ' | ' | ' | ' |
Ending balances at Dec. 31, 2009 | 6,673,530 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 8,211 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 148,703,722 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -142,038,403 | ' | ' | ' | ' | ' | ' | ' |
Beginning balances, shares at Dec. 31, 2009 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 8,211,411 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Sale of preferred stock value, net offering costs | ' | ' | ' | ' | ' | ' | ' | ' | 14,014,724 | 13,344,768 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 19 | 19 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 14,014,705 | 13,344,749 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Sale of preferred stock shares, net offering costs, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 19,000 | 19,217 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Reduction of shares and cash paid in lieu for fractional shares following the reverse split | -146 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -146 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Reduction of shares and cash paid in lieu for fractional shares following the reverse split, Shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -31 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Deemed dividend on series A, B, C, D, E, F preferred stock | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,514,920 | 3,124,876 | ' | ' | ' | ' | ' | ' | -2,514,920 | -3,124,876 | ' |
Exercise of warrants | ' | 317,444 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 85 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 317,359 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Exercise of warrants, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 84,651 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock at conversion of notes payable / Conversion of preferred stock into common stock / Conversion of Series C preferred stock into common stock | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -19 | -19 | ' | ' | ' | ' | ' | ' | ' | ' | 1,994 | 5,190 | ' | ' | ' | ' | ' | ' | ' | ' | -1,975 | -5,171 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock at conversion of notes payable / Conversion of preferred stock into common stock / Conversion of Series C preferred stock into common stock, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -19,000 | -19,217 | ' | ' | ' | ' | ' | ' | ' | ' | 1,993,965 | 5,190,306 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based compensation expense - employee options | 785,943 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 785,943 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | -8,450,922 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -8,450,922 | ' | ' | ' | ' | ' | ' | ' |
Ending balances at Dec. 31, 2010 | 26,685,341 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 15,480 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 182,798,982 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -156,129,121 | ' | ' | ' | ' | ' | ' | ' |
Ending balances, shares at Dec. 31, 2010 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 15,480,302 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Sale of common stock, net of offering costs | 15,644,804 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 21,250 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 15,623,554 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock issued during period value sale, net | 20,959,406 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 8,185 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 20,951,221 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Other comprehensive income/(loss) | -2,298 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -2,298 | ' | ' | ' | ' | ' | ' | ' | ' |
Sale of common stock, net of offering costs, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 21,250,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock issued during period shares, sale, net | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 8,184,556 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock in acquisition | 5,885,323 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,801 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 5,882,522 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock in acquisition, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,800,851 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based compensation expense - employee options | 866,052 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 866,052 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | -13,259,931 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -13,259,931 | ' | ' | ' | ' | ' | ' | ' |
Ending balances at Dec. 31, 2011 | 56,778,697 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 47,716 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 226,122,331 | ' | ' | ' | ' | ' | ' | ' | ' | ' | -2,298 | -169,389,052 | ' | ' | ' | ' | ' | ' | ' |
Ending balances, shares at Dec. 31, 2011 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 47,715,709 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cumulative effect of change in accounting principle | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Other comprehensive income/(loss) | 104 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 104 | ' | ' | ' | ' | ' | ' | ' | ' |
Repurchase of Subject to Vesting Shares | -1,454 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -1,454 |
Cashless exercise of warrants | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Repurchase of Subject to Vesting Shares, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -1,454,079 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Elimination of contingent asset | -886,988 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -886,988 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Exercise of stock options | 2,194 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,190 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Exercise of stock options, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,656 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cancellation of treasury stock shares/Elimination of treasury stock in connection with offering | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based compensation expense - employee options | 1,459,330 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,459,330 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | -15,559,489 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -15,559,489 | ' | ' | ' | ' | ' | ' | ' |
Ending balances at Dec. 31, 2012 | 41,792,394 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 47,720 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 226,696,863 | ' | ' | ' | ' | ' | ' | ' | ' | ' | -2,194 | -184,948,541 | ' | ' | ' | ' | ' | ' | -1,454 |
Ending balances, shares at Dec. 31, 2012 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 46,265,286 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cumulative effect of change in accounting principle | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Sale of common stock, net of offering costs | 25,736,952 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 56,194 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 25,680,758 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Other comprehensive income/(loss) | -18,544 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -18,544 | ' | ' | ' | ' | ' | ' | ' | ' |
Sale of common stock, net of offering costs, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 56,195,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cashless exercise of warrants | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Elimination of contingent liability | 177,500 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 177,500 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock in acquisition | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 250 | ' | ' | ' | ' | ' | ' | ' | ' | ' | -250 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock in acquisition, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 250,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Exercise of stock options, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cancellation of treasury stock shares/Elimination of treasury stock in connection with offering | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -1,454 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,454 |
Cancellation of treasury stock shares/Elimination of treasury stock in connection with offering, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based compensation expense - employee options | 1,599,822 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,599,822 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | -21,480,285 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -21,480,285 | ' | ' | ' | ' | ' | ' | ' |
Ending balances at Dec. 31, 2013 | $47,807,839 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $102,710 | ' | ' | ' | ' | ' | ' | ' | ' | ' | $254,154,693 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ($20,738) | ($206,428,826) | ' | ' | ' | ' | ' | ' | ' |
Ending balances, shares at Dec. 31, 2013 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 102,710,286 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Consolidated_Statements_of_Sto1
Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical) (USD $) | 12 Months Ended | 12 Months Ended | 12 Months Ended | 12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||
Dec. 31, 2013 | Dec. 31, 2011 | Dec. 31, 2000 | Dec. 31, 1997 | Dec. 31, 2002 | Dec. 31, 2002 | Dec. 31, 2003 | Dec. 31, 2003 | Dec. 31, 2009 | Dec. 31, 2009 | Dec. 31, 2004 | Dec. 31, 2006 | Dec. 31, 2009 | Dec. 31, 2009 | Dec. 31, 2010 | Dec. 31, 2010 | Dec. 31, 2000 | Dec. 31, 2002 | Dec. 31, 2002 | Dec. 31, 2009 | Dec. 31, 2009 | Dec. 31, 2009 | Dec. 31, 2009 | Dec. 31, 2010 | Dec. 31, 2010 | Dec. 31, 2013 | Dec. 31, 2011 | Dec. 31, 1997 | Dec. 31, 2003 | Dec. 31, 2003 | Dec. 31, 2004 | Dec. 31, 2006 | Dec. 31, 2013 | Dec. 31, 2011 | Dec. 31, 2000 | Dec. 31, 1997 | Dec. 31, 2002 | Dec. 31, 2002 | Dec. 31, 2003 | Dec. 31, 2003 | Dec. 31, 2009 | Dec. 31, 2009 | Dec. 31, 2004 | Dec. 31, 2006 | Dec. 31, 2009 | Dec. 31, 2009 | Dec. 31, 2010 | Dec. 31, 2010 | |
Preferred Stock Par Value at $1.50 [Member] | Preferred Stock Par Value at $10.00 [Member] | Common Stock Selling Price at $0.40 [Member] | Common Stock Selling Price at $1.00 [Member] | Series A Preferred Stock [Member] | Series B Preferred Stock [Member] | Common Stock Selling Price at $1.50 [Member] | Common Stock Selling Price at $2.75 [Member] | Series C Preferred Stock [Member] | Series D Preferred Stock [Member] | Series E Preferred Stock [Member] | Series F Preferred Stock [Member] | Cumulative Convertible Preferred Stock, Series A Through C [Member] | Cumulative Convertible Preferred Stock, Series A Through C [Member] | Cumulative Convertible Preferred Stock, Series A Through C [Member] | Convertible Preferred Stock, Series A (2009) [Member] | Cumulative Convertible Preferred Stock, Series B Through F (2009-2010) [Member] | Cumulative Convertible Preferred Stock, Series B Through F (2009-2010) [Member] | Cumulative Convertible Preferred Stock, Series B Through F (2009-2010) [Member] | Cumulative Convertible Preferred Stock, Series B Through F (2009-2010) [Member] | Cumulative Convertible Preferred Stock, Series B Through F (2009-2010) [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | |||||
Preferred Stock Par Value at $1.50 [Member] | Preferred Stock Par Value at $10.00 [Member] | Series A Preferred Stock [Member] | Series B Preferred Stock [Member] | Series C Preferred Stock [Member] | Series D Preferred Stock [Member] | Series E Preferred Stock [Member] | Series F Preferred Stock [Member] | Common Stock Selling Price at $0.40 [Member] | Common Stock Selling Price at $1.00 [Member] | Common Stock Selling Price at $1.50 [Member] | Common Stock Selling Price at $2.75 [Member] | Preferred Stock Par Value at $1.50 [Member] | Preferred Stock Par Value at $10.00 [Member] | Common Stock Selling Price at $0.40 [Member] | Common Stock Selling Price at $1.00 [Member] | Series A Preferred Stock [Member] | Series B Preferred Stock [Member] | Common Stock Selling Price at $1.50 [Member] | Common Stock Selling Price at $2.75 [Member] | Series C Preferred Stock [Member] | Series D Preferred Stock [Member] | Series E Preferred Stock [Member] | Series F Preferred Stock [Member] | |||||||||||||||||||||||||
Sale of stock, offering costs One | ' | $1,548,123 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $1,548,123 | ' | ' | ' | ' | ' | ' | $1,548,123 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Preferred Stock, Sale price per share One | ' | ' | ' | ' | $1.50 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $1.50 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $1.50 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Sale of stock, offering costs Two | ' | 1,355,196 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,355,196 | ' | ' | ' | ' | ' | ' | 1,355,196 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Preferred Stock, Sale price per share Two | ' | ' | ' | ' | ' | $10 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $10 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $10 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Common Stock, Sale price per share One | ' | ' | ' | ' | ' | ' | $0.40 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0.40 | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0.40 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Common Stock, Sale price per share Two | ' | ' | ' | ' | ' | ' | ' | $1 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $1 | ' | ' | ' | ' | ' | ' | ' | ' | ' | $1 | ' | ' | ' | ' | ' | ' | ' | ' |
Common Stock, Sale price per share Three | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $1.50 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $1.50 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $1.50 | ' | ' | ' | ' | ' |
Common stock, Sale price per share | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $2.75 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $2.75 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $2.75 | ' | ' | ' | ' |
Sale of stock for Common stock, Preferred stock, Series A, B, C, D, E, F Preferred Stock, offering costs | $2,360,548 | ' | $76,500 | $9,976 | ' | ' | ' | ' | $389,125 | $247,643 | ' | ' | $143,885 | $1,327,664 | $2,162,787 | $1,655,234 | $76,500 | ' | ' | $389,125 | $247,643 | $143,885 | $1,327,664 | $2,162,787 | $1,655,234 | $2,360,548 | ' | $9,976 | ' | ' | ' | ' | $2,360,548 | ' | $76,500 | $9,976 | ' | ' | ' | ' | $389,125 | $247,643 | ' | ' | $143,885 | $1,327,664 | $2,162,787 | $1,655,234 |
Consolidated_Statements_of_Cas
Consolidated Statements of Cash Flows (USD $) | 12 Months Ended | 211 Months Ended | |
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | |
Cash flows from operating activities: | ' | ' | ' |
Net loss | ($21,480,285) | ($15,559,489) | ($208,657,433) |
Adjustments to reconcile net loss to net cash used in operating activities: | ' | ' | ' |
Depreciation and amortization | 39,517 | 90,047 | 10,614,754 |
Loss on disposals of equipment | ' | 4,503 | 61,315 |
Loss on fair value of warrants | ' | ' | 12,239,688 |
Loss/(gain) on change in fair value of contingent consideration | 35,000 | -69,602 | -1,493,907 |
Amortization of debt discount | ' | ' | 450,000 |
Forgiveness of employee receivable | ' | ' | 30,036 |
Impairment loss - write-off of goodwill | ' | ' | 5,702,130 |
Share-based compensation expense related to employee stock options and restricted stock issued | 1,599,822 | 1,459,330 | 13,149,146 |
Expenses related to options issued to non-employees | ' | ' | 204,664 |
Expenses paid by issuance of common stock | ' | ' | 1,341,372 |
Expenses paid by issuance of warrants | ' | ' | 573,357 |
Expenses paid by issuance of preferred stock | ' | ' | 142,501 |
Expenses related to stock warrants issued | ' | ' | 612,000 |
Equity in loss of investee | ' | ' | 178,936 |
In-process research and development | ' | ' | 10,422,130 |
Write-off of license agreement | ' | ' | 152,866 |
Impairment of equipment | ' | 402,739 | 510,739 |
Cumulative effect of change in accounting principle | ' | ' | 25,821 |
Amortization of premium/(accretion of discount) on investments in securities | ' | 21,840 | -1,571,502 |
Changes in assets and liabilities, net of effect of acquisitions: | ' | ' | ' |
Increase in prepaid and other current assets | -489,625 | -388,704 | -1,445,484 |
Increase in accounts payable and accrued liabilities | 2,506,609 | 120,468 | 4,801,787 |
Net cash used in operating activities | -17,788,962 | -13,918,868 | -151,955,084 |
Cash flows from investing activities: | ' | ' | ' |
Purchases of certificates of deposit | -21,967,035 | -15,822,000 | -45,950,214 |
Proceeds from maturities of certificates of deposit | 17,248,000 | 8,675,000 | 26,939,330 |
Proceeds from sale of certificate of deposit | ' | 248,000 | 248,000 |
Purchases of other investment securities | ' | ' | -111,183,884 |
Proceeds from maturities and sales of other investment securities | ' | ' | 112,788,378 |
Purchases of property and equipment | -46,781 | -266,175 | -1,783,585 |
Proceeds from sale of property and equipment | ' | ' | 66,920 |
Cash paid for acquisitions, net of cash acquired | ' | ' | 32,395 |
Payment on obligation under license agreement | ' | ' | -106,250 |
Issuance of note receivable - related party | ' | ' | -35,000 |
Payments on note receivable | ' | ' | 405,993 |
Advance to investee | ' | ' | -90,475 |
Cash transferred in rescission of acquisition | ' | ' | -19,475 |
Cash received in rescission of acquisition | ' | ' | 230,000 |
Net cash used in investing activities | -4,765,816 | -7,165,175 | -18,457,867 |
Cash flows from financing activities: | ' | ' | ' |
Proceeds from sale of common stock | 28,097,500 | ' | 151,756,371 |
Proceeds from exercise of stock options | ' | 2,194 | 714,561 |
Proceeds from sale or exercise of warrants | ' | ' | 14,714,258 |
Proceeds from sale of preferred stock | ' | ' | 44,474,720 |
Repurchase of Subject to Vesting Shares | ' | -1,454 | -1,454 |
Repurchase of warrants | ' | ' | -55,279 |
Payments for financing and offering costs | -2,360,548 | ' | -16,257,915 |
Payments on notes payable and long-term debt | ' | ' | -605,909 |
Proceeds from issuance of notes payable and detachable warrants | ' | ' | 1,344,718 |
Cash paid in lieu of fractional shares for reverse stock split | ' | ' | -146 |
Net cash provided by financing activities | 25,736,952 | 740 | 196,083,925 |
Effect of exchange rate changes on cash | -1,522 | 13,796 | 10,118 |
Net increase (decrease) in cash and cash equivalents | 3,180,652 | -21,069,507 | 25,681,092 |
Cash and cash equivalents at beginning of period | 22,500,440 | 43,569,947 | ' |
Cash and cash equivalents at end of period | $25,681,092 | $22,500,440 | $25,681,092 |
Description_of_Business
Description of Business | 12 Months Ended | |
Dec. 31, 2013 | ||
Accounting Policies [Abstract] | ' | |
Description of Business | ' | |
1 | Description of Business | |
Mast Therapeutics, Inc., a Delaware corporation (“Mast Therapeutics,” “we” or “our company”), is a biopharmaceutical company focused on developing therapies for serious or life-threatening diseases. We have devoted substantially all of our resources to research and development (“R&D”), and acquisition of our product candidates. We have not yet marketed or sold any products or generated any significant revenue. Through our acquisition of SynthRx, Inc. in 2011, we acquired our Membrane Adhesion & Sealant Technology (MAST) platform, which includes proprietary poloxamer-related data and know-how developed over two decades of clinical, nonclinical and manufacturing experience, and we are leveraging the MAST platform to develop MST-188 for serious or life-threatening diseases and conditions typically characterized by impaired microvascular blood flow and damaged cell membranes. | ||
In March 2013, we merged our wholly-owned subsidiary, Mast Therapeutics, Inc., with and into us and changed our name from ADVENTRX Pharmaceuticals, Inc. to Mast Therapeutics, Inc. The merger had no effect on our financial statements. |
Summary_of_Significant_Account
Summary of Significant Accounting Policies | 12 Months Ended | ||||||||||||
Dec. 31, 2013 | |||||||||||||
Accounting Policies [Abstract] | ' | ||||||||||||
Summary of Significant Accounting Policies | ' | ||||||||||||
2 | Summary of Significant Accounting Policies | ||||||||||||
Basis of Presentation | |||||||||||||
The consolidated financial statements include the accounts of Mast Therapeutics and its wholly-owned subsidiaries, SD Pharmaceuticals, Inc. (“SD Pharmaceuticals”) and SynthRx, Inc. (“SynthRx”). All intercompany accounts and transactions have been eliminated in consolidation. | |||||||||||||
We accounted for the acquisition of SynthRx in accordance with Accounting Standards Codification (“ASC”) Topic 805, Business Combinations (“ASC Topic 805”). ASC Topic 805 establishes principles and requirements for recognizing and measuring the total consideration transferred to and the assets acquired, liabilities assumed and any non-controlling interests in the acquired target in a business combination. ASC Topic 805 also provides guidance for recognizing and measuring goodwill acquired in a business combination; requires purchased in-process research and development (“IPR&D”) to be capitalized at fair value as an intangible asset at the time of acquisition; requires acquisition-related expenses and restructuring costs to be recognized separately from the business combination; expands the definition of what constitutes a business; and requires the acquirer to disclose information that users may need to evaluate and understand the financial effect of the business combination. | |||||||||||||
Use of Estimates | |||||||||||||
The preparation of financial statements in conformity with United States generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates, including estimates related to IPR&D, goodwill, R&D expenses and share-based compensation expenses. We base our estimates on historical experience and various other relevant assumptions we believe to be reasonable under the circumstances. Actual results may differ from these estimates. | |||||||||||||
Fair Value of Financial Instruments | |||||||||||||
Our investment securities are, and prior to its settlement our contingent liability was, carried at fair value (see Note 5). Cash equivalents, prepaid expenses and other current assets, accounts payable and accrued liabilities, are carried at cost, which we believe approximates fair value due to the short-term maturities of these instruments. | |||||||||||||
Cash Equivalents | |||||||||||||
We consider all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. Cash equivalents are carried at cost, which we believe approximates fair value due to the short-term maturities of these instruments. At December 31, 2013 and 2012, we had $1.3 million and $1.0 million of cash equivalents, respectively. | |||||||||||||
Investment Securities | |||||||||||||
Investment securities are marketable equity or debt securities. All of our investment securities are “available-for-sale” securities and carried at fair value (see Note 5). Fair value for securities with short maturities and infrequent secondary market trades typically is determined by using a curve-based evaluation model that utilizes quoted prices for similar securities. The evaluation model takes into consideration the days to maturity, coupon rate and settlement date convention. Net unrealized gains or losses on these securities are included in accumulated other comprehensive loss, which is a separate component of stockholders’ equity. Realized gains and realized losses are included in other income/(expense), while amortization of premiums and accretion of discounts are included in interest income. Interest and dividends on available-for-sale securities are included in interest income. We periodically evaluate our investment securities for impairment. If we determine that a decline in fair value of any investment security is other than temporary, then the cost basis would be written down to fair value and the decline in value would be charged to earnings. | |||||||||||||
Our investment securities are under the custodianship of a major financial institution and consist of FDIC-insured certificates of deposit. We have classified all of our available-for-sale investment securities, including those with maturities beyond one year from the date of purchase, as current assets on our consolidated balance sheets because we consider them to be highly liquid and available for use, if needed, in current operations. As of December 31, 2013, $2.9 million of our investment securities had contractual maturity dates of more than one year and less than or equal to 18 months and none were greater than 18 months. | |||||||||||||
Property and Equipment | |||||||||||||
Property and equipment are stated at cost, less accumulated depreciation. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets (generally three to five years). Leasehold improvements are amortized over the economic life of the asset or the lease term, whichever is shorter. Repairs and maintenance are expensed as incurred. | |||||||||||||
In accordance with ASC Topic 360-10, Property, Plant and Equipment – Overall, we test for recoverability of long-lived assets, including property and equipment, if events or changes in circumstances indicate that the carrying amount for the assets may not be recoverable. If our assessment indicates impairment, we measure the impairment loss as the amount by which the carrying amount exceeds fair value of the assets. Fair value determinations are based on an undiscounted cash flow model, or independent appraisals, as appropriate. | |||||||||||||
Intangible Assets – Goodwill and Acquired In-Process Research & Development | |||||||||||||
In accordance with ASC Topic 350, Intangibles – Goodwill and Other (“ASC Topic 350”), our goodwill and acquired IPR&D are determined to have indefinite lives and, therefore, are not amortized. Instead, they are tested for impairment annually and between annual tests if we become aware of an event or a change in circumstances that would indicate the carrying value may be impaired. We perform our annual impairment testing as of September 30 of each year. Pursuant to Accounting Standards Update, or ASU, No. 2011-08, Intangibles – Goodwill and Other (Topic 350): Testing Goodwill for Impairment, and No. 2012-02, Intangibles – Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment, we have the option to first assess qualitative factors to determine whether the existence of events or circumstances leads us to determine that it is more likely than not (that is, a likelihood of more than 50%) that our goodwill or our acquired IPR&D is impaired. If we choose to first assess qualitative factors and we determine that it is not more likely than not goodwill or acquired IPR&D is impaired, we are not required to take further action to test for impairment. We also have the option to bypass the qualitative assessment and perform only the quantitative impairment test, which we may choose to do in some periods but not in others. | |||||||||||||
In performing the quantitative assessment for goodwill, we utilize the two-step approach prescribed under ASC Topic 350. Step 1 requires a comparison of the carrying value of a reporting unit, including goodwill, to its estimated fair value. We test for impairment at the entity level because we operate on the basis of a single reporting unit. If our carrying value exceeds our fair value, we then perform Step 2 to measure the amount of impairment loss, if any. In Step 2, we estimate the fair value of our individual assets, including identifiable intangible assets, and liabilities to determine the implied fair value of goodwill. We then compare the carrying value of our goodwill to its implied fair value. The excess of the carrying value of goodwill over its implied fair value, if any, is recorded as an impairment charge. | |||||||||||||
In performing the quantitative assessment for acquired IPR&D, we compare the carrying value of acquired IPR&D to its estimated fair value. We calculate the estimated fair value of acquired IPR&D by using the Multi-Period Excess Earnings Method, or MPEEM, which is a form of the income approach. Under the MPEEM, the fair value of an intangible asset is equal to the present value of the asset’s incremental after-tax cash flows (excess earnings) remaining after deducting the market rates of return on the estimated value of contributory assets (contributory charge) over its remaining useful life. This method requires us to make long-term projections of revenues and expenses related to development and commercialization of the acquired assets and assumptions regarding the rate of return on contributory assets, the weighted average cost of capital and the probability adjustment factor for estimated future after-tax cash flows. The excess of the carrying value over its estimated fair value is recorded as an impairment charge. | |||||||||||||
All impairment charges are recorded to our consolidated statements of operations and comprehensive income/(loss). Our determinations as to whether, and, if so, the extent to which, goodwill and acquired IPR&D become impaired are highly judgmental and based on significant assumptions regarding our projected future financial condition and operating results, changes in the manner of our use and development of the acquired assets, our overall business strategy, and regulatory, market and economic environment and trends. We perform our annual impairment testing as of September 30 each year. As of September 30, 2013, no impairment of goodwill or acquired IPR&D was identified. | |||||||||||||
For acquisitions prior to January 1, 2009, the estimated fair value of acquired IPR&D was expensed immediately for projects that, as of the acquisition date, had not reached technological feasibility, had no alternative future use and had uncertainty in receiving future economic benefits from the acquired IPR&D. In the year ended December 31, 2006, we recorded $10.4 million of IPR&D expense related to our acquisition of SD Pharmaceuticals. | |||||||||||||
Concentration of Credit Risk and Significant Sources of Supply | |||||||||||||
Financial instruments that potentially subject us to concentrations of credit risk are primarily cash, cash equivalents and investment securities. We have a board-approved investment policy that sets our investment parameters and limitations with objectives of preserving principal and liquidity. Our cash and cash equivalent balances consist primarily of money market accounts under the custodianship of major financial institutions. Investment securities are invested in accordance with our investment policy. We do not have any financial instruments with off-balance-sheet risk of accounting loss. | |||||||||||||
We rely on single-source, third-party manufacturers and suppliers for production and supply of key components of our product candidates, and for production of the final drug products themselves. If these single-source, third-party manufacturers and suppliers are unable to continue providing a key component or the final drug products, the initiation or progress of any clinical studies of our product candidates may be severely impeded. | |||||||||||||
Foreign Currency | |||||||||||||
Net foreign currency gains (losses) resulting from transactions in currencies other than the functional currency are included in other income (expense) in our consolidated statement of operations and comprehensive income/(loss). For the years ended December 31, 2013 and 2012, we recorded net foreign currency gains of less than $1,000 and $53,000 respectively. As of both December 31, 2013 and 2012, less than 1% of our total liabilities were denominated in currencies other than the U.S. dollar, which is our functional currency. | |||||||||||||
Research and Development Expense | |||||||||||||
R&D costs are charged to expense as incurred and include, but are not limited to, clinical and nonclinical study costs, research-related manufacturing and related costs, employee salaries and benefits, consulting services fees and share-based compensation cost. Clinical study costs include, but are not limited to, clinical research organization fees, investigator fees, site costs and, as applicable, comparator drug costs. Costs for certain R&D activities, such as research-related manufacturing and clinical studies, are recognized based on an evaluation of the percentage of work completed or the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, duration of the study and/or information provided to us by our vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid expenses or accrued R&D costs. | |||||||||||||
Advance payments to third parties, including nonrefundable amounts, for goods and services that will be used or rendered for future R&D activities are deferred and capitalized, then expensed as the services are performed or as the underlying goods are delivered. If we do not expect the services to be rendered or goods to be delivered, any remaining capitalized amounts for nonrefundable advance payments are charged to expense immediately. | |||||||||||||
Milestone payments that we make in connection with in-licensed technology or product candidates are expensed as incurred when there is uncertainty in receiving future economic benefits from the licensed technology or product candidates. We consider the future economic benefits from the licensed technology or product candidates to be uncertain until such licensed technology is incorporated into products that, or such product candidates, are approved for marketing by the FDA or when other significant risk factors are abated. For accounting purposes, management has viewed future economic benefits for all of our licensed technology or product candidates to be uncertain. | |||||||||||||
Share-Based Compensation | |||||||||||||
Share-based compensation cost is measured at the grant date, based on the estimated fair value of the award using the Black-Scholes valuation model, and is recognized as expense over the vesting period on a straight-line basis. Share-based compensation expense recognized in the consolidated statements of operations for the years ended December 31, 2013 and 2012 is based on awards ultimately expected to vest and has been reduced for estimated forfeitures. This estimate will be revised in subsequent periods if actual forfeitures differ from those estimates. None of our outstanding share-based awards have market or performance conditions. | |||||||||||||
Patent Costs | |||||||||||||
Legal costs in connection with approved patents and patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. These costs are recorded as selling, general and administrative expenses in our consolidated statement of operations and comprehensive income/(loss). | |||||||||||||
Income Taxes | |||||||||||||
We account for income taxes and the related accounts under the liability method. Deferred tax assets and liabilities are determined based on the differences between the financial statement carrying amounts and the income tax basis of assets and liabilities. A valuation allowance is applied against any net deferred tax asset if, based on available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. | |||||||||||||
The tax effects from an uncertain tax position can be recognized in our consolidated financial statements only if the position is more likely than not of being sustained upon an examination by tax authorities. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. | |||||||||||||
We account for interest and penalties related to income tax matters, if any, in income tax expense. | |||||||||||||
Comprehensive Income/(Loss) | |||||||||||||
Comprehensive income or loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources, including foreign currency translation adjustments and unrealized gains and losses on marketable securities. We present comprehensive income/(loss) in our consolidated statement of operations and comprehensive income/(loss). | |||||||||||||
Net Loss per Common Share | |||||||||||||
Basic and diluted net loss per common share is calculated by dividing the net loss applicable to common stock for the periods presented by the weighted-average number of common shares outstanding during those periods, respectively, without consideration for outstanding common stock equivalents because their effect would have been anti-dilutive. Common stock equivalents are included in the calculation of diluted earnings per common share only if their effect is dilutive. For the years ended December 31, 2013 and 2012, our outstanding common stock equivalents consisted of options and warrants to purchase shares of our common stock. The weighted-average number of those common stock equivalents outstanding for each of the periods presented is set forth in the table below: | |||||||||||||
Years ended December 31, | |||||||||||||
2013 | 2012 | ||||||||||||
Warrants | 31,576,405 | 17,093,296 | |||||||||||
Options | 5,742,168 | 3,111,854 | |||||||||||
37,318,573 | 20,205,150 | ||||||||||||
Supplemental Cash Flow Information | |||||||||||||
Years ended December 31, | Inception | ||||||||||||
(June 12, 1996) | |||||||||||||
through | |||||||||||||
2013 | 2012 | December 31, 2013 | |||||||||||
Supplemental disclosures of cash flow information: | |||||||||||||
Interest paid | $ | — | $ | — | $ | 180,719 | |||||||
Supplemental disclosures of non-cash investing and financing activities: | |||||||||||||
Issuance of warrants, common stock and preferred stock for: | |||||||||||||
Conversion of notes payable and accrued interest | — | — | 1,213,988 | ||||||||||
Prepaid services to consultants | — | — | 1,482,781 | ||||||||||
Conversion of preferred stock | — | — | 13,674 | ||||||||||
Acquisitions | — | — | 30,666,878 | ||||||||||
Issuance of common stock to pay dividends | — | — | 213,000 | ||||||||||
Issuance of common stock for milestone achievement | 250 | — | 250 | ||||||||||
Financial advisor services in conjunction with financings | — | — | 3,477,571 | ||||||||||
Underwriter commissions in conjunction with financings | — | — | 766,784 | ||||||||||
Acquisition of treasury stock in settlement of a claim | — | — | 34,737 | ||||||||||
Cancellation of treasury stock | — | — | (34,737 | ) | |||||||||
Assumptions of liabilities in acquisitions | — | — | 1,531,806 | ||||||||||
Fair value of contingent liabilities, net of contingent assets, recorded at acquisition date | — | — | 784,419 | ||||||||||
Acquisition of license agreement for long-term debt | — | — | 161,180 | ||||||||||
Unrealized loss/(gain) on investment securities | 18,544 | (104 | ) | 18,582 | |||||||||
Disposal of equipment in conjunction with settlement of a liability | 99,875 | — | 99,875 | ||||||||||
Cashless exercise of warrants | — | — | 4,312 | ||||||||||
Dividends accrued | — | — | 621,040 | ||||||||||
Trade asset converted to available-for-sale asset | — | — | 108,000 | ||||||||||
Dividends extinguished | — | — | 408,240 | ||||||||||
Trade payable converted to note payable | — | — | 83,948 | ||||||||||
Issuance of warrants for return of common stock | — | — | 50,852 | ||||||||||
Detachable warrants issued with notes payable | — | — | 450,000 | ||||||||||
Cumulative preferred stock dividends | — | — | 13,502,403 | ||||||||||
Recent Accounting Pronouncements | |||||||||||||
In July 2013, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (“ASU 2013-11”). This standard requires an unrecognized tax benefit related to a net operating loss carryforward, a similar tax loss or a tax credit carryforward to be presented as a reduction to a deferred tax asset, unless the tax benefit is not available at the reporting date to settle any additional income taxes under the tax law of the applicable tax jurisdiction. ASU 2013-11 is effective for fiscal years and interim periods beginning after December 15, 2013, with early adoption permitted. We do not believe that the adoption of this standard will have an impact on our consolidated financial position, results of operations or cash flows. |
Acquisition_of_SynthRx
Acquisition of SynthRx | 12 Months Ended | |
Dec. 31, 2013 | ||
Business Combinations [Abstract] | ' | |
Acquisition of SynthRx | ' | |
3 | Acquisition of SynthRx | |
In April 2011, we acquired SynthRx, Inc., a privately-held Delaware corporation, in an all-stock transaction pursuant to an agreement and plan of merger, dated February 12, 2011 (the “Merger Agreement”), by and among us, SRX Acquisition Corporation, a wholly-owned subsidiary of ours, SynthRx and a stockholders’ representative. SynthRx survived the merger transaction as a wholly-owned subsidiary of ours. The merger consideration payable upon completion of the acquisition consisted of (a) 862,078 fully-vested shares of our common stock (the “Fully Vested Shares”) and (b) 1,938,773 shares of our common stock, of which up to approximately 75%, or 1,454,079 shares (the “Subject to Vesting Shares,” and, together with the Fully Vested Shares, the “Closing Shares”), were subject to repurchase by us for $0.001 per share based on the timing and circumstances of achievement of the “First Milestone” under the Merger Agreement, which we considered the dosing of the first patient in the EPIC study, our phase 3 clinical trial of MST-188 in sickle cell disease. In accordance with our repurchase rights under the Merger Agreement, we repurchased all of the Subject to Vesting Shares in December 2012. | ||
In June 2013, in accordance with the terms of the Merger Agreement, we issued an aggregate of 250,000 additional shares of our common stock to the former SynthRx stockholders as a result of achievement of the First Milestone in May 2013. Pursuant to the terms of the Merger Agreement, up to 1,000,000 shares were potentially issuable upon achievement of the First Milestone (the “First Milestone Shares”), but, in accordance with the Merger Agreement, only 250,000 shares were issued based on the timing and circumstances of achievement of the First Milestone. As a former SynthRx stockholder, in accordance with the terms of the Merger Agreement, R. Martin Emanuele, our Senior Vice President, Development, received 52,543 of the shares we issued to the former SynthRx stockholders in June 2013. | ||
Under the Merger Agreement, we are obligated to issue up to an aggregate of 12,478,050 additional shares of our common stock to the former SynthRx stockholders in the event of achievement of regulatory milestones as follows: (a) 3,839,400 shares (the “Second Milestone Shares”) upon the FDA’s acceptance for review of a new drug application covering the use of purified poloxamer 188 for the treatment of sickle cell crisis in children (the “188 NDA”), which is defined in the Merger Agreement as the “Second Milestone,” and (b) 8,638,650 shares (the “Third Milestone Shares” and, collectively with the First Milestone Shares and the Second Milestone Shares, the “Milestone Shares”) upon the FDA’s approval of the 188 NDA, which is defined in the Merger Agreement as the “Third Milestone.” | ||
Based on the estimated fair value as of April 8, 2011, the acquisition date, of the Closing Shares and the Milestone Shares, the total purchase price was approximately $6.7 million. | ||
Acquired In-Process Research and Development | ||
Our acquired IPR&D was the estimated fair value as of the acquisition date of MST-188, which was SynthRx’s lead product candidate. We determined that the estimated fair value of the MST-188 program was $6.5 million as of the acquisition date using the MPEEM (see Note 2). | ||
To calculate fair value of the MST-188 program under the MPEEM, we used probability-weighted cash flows discounted at a rate considered appropriate given the significant inherent risks associated with drug development by development-stage companies. Cash flows were calculated based on estimated projections of revenues and expenses related to MST-188 in sickle cell disease and then reduced by a contributory charge on requisite assets employed. Contributory assets included debt-free working capital, net fixed assets and assembled workforce. Rates of return on the contributory assets were based on rates used for comparable market participants. Cash flows were assumed to extend through the market exclusivity period estimated to be provided by orphan drug designation. The resultant cash flows were then discounted to present value using a weighted-average cost of equity capital for companies with profiles substantially similar to that of SynthRx, which we believe represents the rate that market participants would use to value the assets. We compensated for the phase of development of this program by applying a probability factor to our estimation of the expected future cash flows. The projected cash flows were based on significant assumptions, such as the time and resources needed to complete the development and approval of MST-188 in sickle cell disease, estimates of revenue and operating profit related to the program considering its stage of development, the life of the potential commercialized product and associated risks, including the inherent difficulties and uncertainties in drug development, such as obtaining marketing approval from the FDA and other regulatory agencies, and risks related to the viability of and potential alternative treatments in any future target markets. | ||
Goodwill | ||
A value of $3.0 million, representing the difference between the total purchase price and the aggregate fair values of tangible and intangible assets acquired, less liabilities assumed, was recorded as goodwill. We acquired SynthRx to expand our product pipeline, enter into new therapeutic areas and address unmet market needs. These are among the factors that contributed to a purchase price for the SynthRx acquisition that resulted in the recognition of goodwill. | ||
Deferred Income Tax Liability | ||
The $2.6 million recorded for deferred income tax liability resulting from the acquisition reflects the tax impact of the difference between the book basis and tax basis of acquired IPR&D. Such deferred income tax liability cannot be used to offset deferred tax assets when analyzing our end of year valuation allowance as the acquired IPR&D is considered to have an indefinite life until we complete or abandon development of MST-188. | ||
Contingent Consideration | ||
The Milestone Shares and the Subject to Vesting Shares were considered contingent consideration at the acquisition date because our obligation to issue the Milestone Shares and our repurchase rights with respect to the Subject to Vesting Shares were contingent on future events. To determine the classification of the fair value of this contingent consideration as a liability or equity, we reviewed ASC Topic 815-40, Derivatives and Hedging – Contracts in Entity’s Own Equity (“ASC 815-40”), which requires that contingent consideration arrangements that include potential net cash settlements or variable provisions be classified as a liability (or an asset, as applicable). Such classification requires a fair value measurement initially and subsequently at each reporting date. Changes in the fair value of contingent consideration classified as a liability or an asset are recognized in earnings until the contingent consideration arrangement is settled. Classification as equity requires fair value measurement initially and there are no subsequent re-measurements. Settlement of equity-classified contingent consideration is accounted for within equity. | ||
The probability-weighted fair values of the Second Milestone Shares and the Third Milestone Shares were recorded as equity as there is no net cash settlement provision and the number of shares that ultimately may be issued upon achievement of each of those milestones is fixed. However, the probability-weighted fair value of the First Milestone Shares was recorded as a contingent liability and the probability-weighted fair value of the Subject to Vesting Shares was recorded as a contingent asset because there was variability with respect to the number of shares that we ultimately would be required to issue or permitted to repurchase, respectively, based on the circumstances of achievement of the First Milestone, as described above. | ||
The contingent liability related to the First Milestone Shares was eliminated, or “settled,” in May 2013 upon achievement of the First Milestone and our subsequent issuance of 250,000 of the First Milestone Shares. The contingent asset related to the Subject to Vesting Shares was settled in December 2012 by our exercise in full of our repurchase option and purchase of the Subject to Vesting Shares from the former SynthRx stockholders for $0.001 per share. In accordance with ASC 815-40, we remeasured the contingent liability and contingent asset as of their respective settlement dates. |
Investment_Securities
Investment Securities | 12 Months Ended | |
Dec. 31, 2013 | ||
Investments Debt And Equity Securities [Abstract] | ' | |
Investment Securities | ' | |
4 | Investment Securities | |
At December 31, 2013, the fair value of our investment securities was $18,711,448. The cost basis of such investments was $18,730,030 and net unrealized losses were $18,582. |
Fair_Value_of_Financial_Instru
Fair Value of Financial Instruments | 12 Months Ended | ||||||||||||||||
Dec. 31, 2013 | |||||||||||||||||
Fair Value Disclosures [Abstract] | ' | ||||||||||||||||
Fair Value of Financial Instruments | ' | ||||||||||||||||
5 | Fair Value of Financial Instruments | ||||||||||||||||
Our investment securities are and, prior to its settlement, our liability for contingent consideration related to the SynthRx acquisition was carried at fair value. The fair value of financial assets and liabilities is measured under a framework that establishes “levels” which are defined as follows: Level 1 fair value is determined from observable, quoted prices in active markets for identical assets or liabilities. Level 2 fair value is determined from quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar items, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability. Level 3 fair value is determined using the entity’s own assumptions about the inputs that market participants would use in pricing an asset or liability. | |||||||||||||||||
The fair values at December 31, 2013 and 2012 of our investment securities and our contingent liability related to the SynthRx acquisition are summarized in the following tables: | |||||||||||||||||
December 31, 2013 | |||||||||||||||||
Total Fair | Fair Value Determined Under: | ||||||||||||||||
Value | (Level 1) | (Level 2) | (Level 3) | ||||||||||||||
Investment securities | $ | 18,711,448 | $ | — | $ | 18,711,448 | $ | — | |||||||||
Contingent liability | $ | — | $ | — | $ | — | $ | — | |||||||||
December 31, 2012 | |||||||||||||||||
Total Fair | Fair Value Determined Under: | ||||||||||||||||
Value | (Level 1) | (Level 2) | (Level 3) | ||||||||||||||
Investment securities | $ | 14,010,962 | $ | — | $ | 14,010,962 | $ | — | |||||||||
Contingent liability | $ | (142,500 | ) | $ | — | $ | — | $ | (142,500 | ) | |||||||
A reconciliation of the contingent liability that was measured and recorded at fair value on a recurring basis using significant unobservable inputs (Level 3) in the year ended December 31, 2013 until it was settled on May 30, 2013 is as follows: | |||||||||||||||||
Year ended December 31, 2013 | |||||||||||||||||
Contingent Liability | |||||||||||||||||
Beginning balance | $ | (142,500 | ) | ||||||||||||||
Settlement on May 30, 2013 | 177,500 | ||||||||||||||||
Total net unrealized losses included in earnings | (35,000 | ) | |||||||||||||||
Ending balance | $ | — | |||||||||||||||
Change in unrealized losses for the period included in earnings for assets or liabilities held during 2013 | $ | (35,000 | ) | ||||||||||||||
Property_and_Equipment
Property and Equipment | 12 Months Ended | ||||||||||
Dec. 31, 2013 | |||||||||||
Property Plant And Equipment [Abstract] | ' | ||||||||||
Property and Equipment | ' | ||||||||||
6 | Property and Equipment | ||||||||||
Property and equipment at December 31, 2013 and 2012 were as follows: | |||||||||||
Useful Lives | 2013 | 2012 | |||||||||
Office furniture, computer and lab equipment | 3 - 5 years | $ | 275,035 | $ | 421,494 | ||||||
Computer software | 3 years | 57,526 | 62,509 | ||||||||
Leasehold improvements | 1 year | 34,900 | 34,900 | ||||||||
Equipment in progress | n/a | — | — | ||||||||
367,461 | 518,903 | ||||||||||
Less accumulated depreciation and amortization | (261,714 | ) | (320,545 | ) | |||||||
Property and equipment, net | $ | 105,747 | $ | 198,358 | |||||||
Depreciation and amortization expense was $39,517 and $90,047 for the years ended December 31, 2013 and 2012, respectively. | |||||||||||
In connection with our determination in 2012 to discontinue independent development of ANX-514, we assessed the classification and recoverability, at the end of each fiscal quarter, of certain equipment held and used in research-related manufacturing of ANX-514 (the “ANX-514 equipment”) by our contract manufacturer. The original cost of the ANX-514 equipment was $0.6 million. We determined, based on an independent appraisal, that the carrying amount of the ANX-514 equipment exceeded its estimated fair value and was not recoverable. For the year ended December 31, 2012, we recorded an impairment loss of $0.4 million, which was the difference between the carrying amount and estimated fair value at December 31, 2012, as a research and development expense in our consolidated statement of operations and comprehensive income/(loss). The ANX-514 equipment was not classified separately as “held for sale” as of December 31, 2012 because the criteria for that classification, as set forth in ASC Topic 360-10, Property, Plant and Equipment – Overall, were not met. | |||||||||||
In April 2013, in connection with reaching an agreement with our contract manufacturer regarding final payment for ANX-514 research-related manufacturing activities, we agreed to assign ownership of the ANX-514 equipment with a carrying amount of $99,875 to the contract manufacturer. |
Accrued_Liabilities
Accrued Liabilities | 12 Months Ended | ||||||||
Dec. 31, 2013 | |||||||||
Payables And Accruals [Abstract] | ' | ||||||||
Accrued Liabilities | ' | ||||||||
7 | Accrued Liabilities | ||||||||
Accrued liabilities at December 31, 2013 and 2012 were as follows: | |||||||||
2013 | 2012 | ||||||||
Accrued R&D agreement and study expenses | $ | 2,273,860 | $ | 1,203,808 | |||||
Accrued acquisition costs | 44,640 | — | |||||||
Other accrued liabilities | 176,588 | 80,168 | |||||||
Accrued liabilities | $ | 2,495,088 | $ | 1,283,976 | |||||
Capital_Stock_and_Warrants
Capital Stock and Warrants | 12 Months Ended | ||||||||
Dec. 31, 2013 | |||||||||
Equity [Abstract] | ' | ||||||||
Capital Stock and Warrants | ' | ||||||||
8 | Capital Stock and Warrants | ||||||||
Our certificate of incorporation, as amended, authorizes us to issue 500,000,000 shares of common stock, par value $0.001 per share, and 1,000,000 shares of preferred stock, par value $0.001 per share. As of December 31, 2013, 102,710,286 shares of common stock were outstanding and no shares of preferred stock were outstanding. | |||||||||
Underwritten Public Offering of Common Stock and Warrants | |||||||||
In June 2013, we completed an underwritten public offering of 56,195,000 shares of our common stock and warrants to purchase up to 28,097,500 additional shares of our common stock. Of the 56,195,000 shares of our common stock issued, 1,454,079 of such shares were issued from our treasury stock. These securities were offered and sold to the underwriters and the public in units with each unit consisting of one share of common stock and one warrant to purchase up to 0.5 of a share of common stock. The gross proceeds from this financing were $28.1 million and, after deducting underwriting discounts and commissions and our other offering expenses, our net proceeds were $25.7 million. We may receive up to $18.3 million of additional proceeds from the exercise of the warrants issued in the financing. The exercise price of the warrants is $0.65 per share. Subject to certain beneficial ownership limitations, the warrants are exercisable at any time on or before June 19, 2018. | |||||||||
Warrants | |||||||||
At December 31, 2013, outstanding warrants to purchase shares of common stock are as follows: | |||||||||
Warrants | Exercise Price | Expiration Date | |||||||
99,696 | $ | 11.9125 | Jun-14 | ||||||
144,000 | $ | 5.875 | Oct-14 | ||||||
19,007 | $ | 4.475 | Jul-14 | ||||||
14,183 | $ | 4.0625 | Aug-14 | ||||||
36,071 | $ | 3.75 | Jun-14 | ||||||
216,000 | $ | 3.67 | October 2014 | ||||||
1,816,608 | $ | 3.65 | May-15 | ||||||
409,228 | $ | 3.44 | Apr-15 | ||||||
2,046,139 | $ | 2.75 | Jan-16 | ||||||
1,062,500 | $ | 1 | Apr-15 | ||||||
10,625,000 | $ | 1.1 | November 2016 | ||||||
28,097,500 | $ | 0.65 | Jun-18 | ||||||
44,585,932 | |||||||||
Equity_Incentive_Plans
Equity Incentive Plans | 12 Months Ended | ||||||||||||||||
Dec. 31, 2013 | |||||||||||||||||
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | ' | ||||||||||||||||
Equity Incentive Plans | ' | ||||||||||||||||
9 | Equity Incentive Plans | ||||||||||||||||
At December 31, 2013, our equity-based incentive plans consisted of the 2005 Equity Incentive Plan (the “2005 Plan”), the 2005 Employee Stock Purchase Plan (the “Purchase Plan”) and the 2008 Omnibus Incentive Plan (the “Original 2008 Plan”), which has been amended, restated and renamed twice, first in June 2011 as the Amended and Restated 2008 Omnibus Incentive Plan (the “Amended and Restated 2008 Plan”) and again in June 2013 as the 2013 Omnibus Incentive Plan (the “2013 Plan”). During the years ended December 31, 2013 and 2012, all awards granted under our equity-based incentive plans were stock options. The share-based compensation expense from all stock options granted that has been charged to our consolidated statements of operations and comprehensive income/(loss) in those periods was as follows: | |||||||||||||||||
Years Ended December 31, | |||||||||||||||||
2013 | 2012 | ||||||||||||||||
Selling, general and administrative expense | $ | 1,428,437 | $ | 1,381,554 | |||||||||||||
Research and development expense | 171,385 | 77,776 | |||||||||||||||
Share-based compensation expense | $ | 1,599,822 | $ | 1,459,330 | |||||||||||||
2013 Omnibus Incentive Plan | |||||||||||||||||
Our equity-based incentive plans, which are stockholder-approved, are intended to encourage ownership of shares of common stock by our directors, officers, employees, consultants and advisors and to provide additional incentive for them to promote the success of our business through the grant of share-based awards. Following approval of the Original 2008 Plan by our stockholders in May 2008, no awards have been or will be granted under the 2005 Plan, and, following approval by our stockholders of each amendment and restatement of the Original 2008 Plan, no awards have been or will be granted under the terms of the plan in effect immediately prior to such amendment and restatement. | |||||||||||||||||
The 2013 Plan provides for the grant of incentive and non-statutory stock options, as well as share appreciation rights, restricted shares, restricted share units, performance units, shares and other share-based awards. Share-based awards are subject to terms and conditions established by our board of directors or the compensation committee of our board of directors. | |||||||||||||||||
As of December 31, 2013, the maximum aggregate number of shares of our common stock available for grant under the 2013 Plan was 3,251,222 shares. Shares of common stock that are subject to awards granted under the 2013 Plan shall be counted against the shares available for issuance under this plan as one share for each share subject to a stock option or stock appreciation right and as 1.5 shares for each share subject to an award other than a stock option or a stock appreciation right. If any shares of common stock subject to an award under any of our stockholder-approved, equity-based incentive plans are forfeited, expire or are settled for cash pursuant to the terms of an award, the shares subject to the award may be used again for awards under the 2013 Plan to the extent of the forfeiture, expiration or settlement. The shares of common stock will be added back as one share for every share of common stock if the shares were subject to a stock option or stock appreciation right, and as 1.5 shares for every share of common stock if the shares were subject to an award other than a stock option or stock appreciation right. However, the following shares of common stock will not be added to the shares available for issuance under the 2013 Plan: (i) shares tendered by a participant or withheld by us in payment of the purchase price of a stock option, (ii) shares tendered by a participant or withheld by us to satisfy any tax withholding obligation with respect to an option or stock appreciation right, (iii) shares subject to a stock appreciation right that are not issued in connection with the stock settlement of the stock appreciation right on exercise thereof, and (iv) shares reacquired by us on the open market or otherwise using cash proceeds from the exercise of stock options. Shares of common stock under awards made in substitution or exchange for awards previously granted, or the right or obligation to make future awards, in each case by a company acquired by us, or with which we combine, will not reduce the number of shares available for issuance under the 2013 Plan. In addition, if a company acquired by us, or with which we combine, has shares available under a pre-existing plan approved by its stockholders and not adopted in contemplation of such acquisition or combination, the shares available for issuance under such plan (adjusted to reflect the exchange or valuation ratio or other adjustment used in the acquisition or combination) may be used for awards under the 2013 Plan and will not reduce the number of shares of common stock available for issuance under the 2013 Plan; provided, however that awards using such available shares shall not be made after the date awards or grants could have been made under the pre-existing plan, absent the acquisition or combination, and shall only be made to individuals who were not our employees or directors prior to the acquisition or combination. | |||||||||||||||||
Under the 2013 Plan, the purchase price of shares of common stock covered by a stock option cannot be less than 100% of the fair market value of the common stock on the date the stock option is granted. Fair market value of the common stock is generally equal to the closing price for the common stock on the principal securities exchange on which the common stock is traded on the date the stock option is granted (or if there was no closing price on that date, on the last preceding date on which a closing price is reported). Stock option awards generally have ten-year contractual terms and vest over four years based on continuous service; however, the 2013 Plan allows for other vesting periods. | |||||||||||||||||
We canceled options for 227,119 and 236,729 shares of common stock in the years ended December 31, 2013 and 2012, respectively, held by employees and non-employee directors whose service to our company terminated during those respective periods. The shares underlying such options became available for re-issuance as described above under the 2013 Plan or the Amended and Restated 2008 Plan, depending whether the option was canceled before or after June 19, 2013, which was the effective date of the 2013 Plan. | |||||||||||||||||
A summary of all of our option activity as of December 31, 2013 and 2012 and of changes in options outstanding under the plans during the year ended December 31, 2013 is as follows: | |||||||||||||||||
Shares | Weighted- | Weighted- | Aggregate | ||||||||||||||
Underlying | Average | Average | Intrinsic | ||||||||||||||
Options | Exercise | Remaining | Value | ||||||||||||||
Price | Contractual | ||||||||||||||||
Years | |||||||||||||||||
Outstanding at January 1, 2013 | 3,585,743 | $ | 2.31 | ||||||||||||||
Granted | 3,946,204 | $ | 0.51 | ||||||||||||||
Exercised | — | $ | — | ||||||||||||||
Cancelled/forfeited/expired | (227,119 | ) | $ | 0.88 | |||||||||||||
Outstanding at December 31, 2013 | 7,304,828 | $ | 1.38 | 8.57 | $ | 4,517 | |||||||||||
Options exercisable at December 31, 2013 | 2,471,671 | $ | 2.56 | 7.77 | $ | — | |||||||||||
Vested and expected to vest at December 31, 2013 | 7,197,119 | $ | 1.39 | 8.56 | $ | 3,710 | |||||||||||
The weighted-average grant-date fair value of options granted during the years ended December 31, 2013 and 2012 was $0.41 and $0.61, respectively. As of December 31, 2013, there was approximately $2.6 million of unamortized compensation cost related to unvested stock option awards, which is expected to be recognized over a weighted-average period of approximately 2.73 years. | |||||||||||||||||
Our determination of fair value is affected by our stock price as well as a number of assumptions that require judgment. The fair value of each option award is estimated on the date of grant using the Black-Scholes option-valuation model. The assumptions used in the Black-Scholes option-valuation model and the calculation of share-based compensation for option grants to employees and non-employee directors during the years ended December 31, 2013 and 2012 are as follows: | |||||||||||||||||
Years Ended December 31, | |||||||||||||||||
2013 | 2012 | ||||||||||||||||
Risk-free interest rate | 1.0 - 2.0 | % | 0.6 - 0.8 | % | |||||||||||||
Dividend yield | 0 | % | 0 | % | |||||||||||||
Expected volatility | 113 - 132 | % | 131 - 139 | % | |||||||||||||
Expected term (in years) | 5.3 - 6.1 years | 5.2 - 6.1 years | |||||||||||||||
Forfeiture rate (officers and directors) | 0 | % | 0 - 4 | % | |||||||||||||
Forfeiture rate (employees) | 10 | % | 4 | % | |||||||||||||
The risk-free interest rate assumption is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. We have not paid any dividends on common stock since our inception and do not anticipate paying dividends on our common stock in the foreseeable future. The expected option term is computed using the “simplified” method as permitted under the provisions of Staff Accounting Bulletin (“SAB”) 107. SAB 107’s guidance was extended indefinitely by SAB 110. The expected volatility is based on the historical volatility of our common stock based on the daily closing prices. Forfeiture rates are based on the expected forfeiture rates for our unvested stock options, which are based in large part on our historical forfeiture rates, but also on assumptions believed to be reasonable under the circumstances. | |||||||||||||||||
In accordance with ASC 718, Compensation – Stock Compensation, share-based compensation expense associated with the non-employee director options is included with employee share-based compensation expense. | |||||||||||||||||
Employee Stock Purchase Plan | |||||||||||||||||
The Purchase Plan was approved by our stockholders in 2005; however, we have not implemented the Purchase Plan. The Purchase Plan, if implemented, allows all eligible employees to purchase shares of common stock at 85% of the lower of the fair market value on the first or the last day of each offering period. Employees may authorize us to withhold up to 15% of their compensation during any offering period, subject to certain limitations. As of December 31, 2013, a maximum of 276,945 shares of common stock would have been issuable under the Purchase Plan had it been in effect as of that date. This maximum number is subject to an annual automatic increase on January 1 of each year (whether or not we have implemented the Purchase Plan) equal to the lesser of (i) 1% of the number of outstanding shares of common stock on such day, (ii) 30,000 shares or (iii) such other amount as our board of directors may specify. |
Commitments
Commitments | 12 Months Ended | ||||
Dec. 31, 2013 | |||||
Commitments And Contingencies Disclosure [Abstract] | ' | ||||
Commitments | ' | ||||
10 | Commitments | ||||
Operating Leases | |||||
We are obligated under operating leases for office space and equipment. We lease approximately 9,300 square feet of office space for our headquarters in San Diego, California, which lease will expire in January 2015, unless we exercise our option to extend through October 2018. The average rent for this space is $26,677 per month through January 2015. Our option to extend the lease through October 2018 is subject to the landlord’s right to require for its own use all or a portion of the leased premises during such period, which right must be exercised by delivering notice to us within 10 days after receipt of our notice to exercise our option to extend the lease. | |||||
From August 2011 through August 2012, we subleased a portion of our space to another company and received rental income of $3,100 per month, which offset our rent expense. | |||||
We lease copiers under leases that expire in 2015. | |||||
Rent expense was approximately $288,000 and $262,000 during the years ended December 31, 2013 and 2012, respectively. | |||||
Future rental commitments under all operating leases are as follows: | |||||
Year Ending December 31, | |||||
2014 | 327,638 | ||||
2015 | 27,365 | ||||
2016 | — | ||||
2017 | — | ||||
2018 | — | ||||
Total | $ | 355,003 | |||
Income_Taxes
Income Taxes | 12 Months Ended | ||||||||
Dec. 31, 2013 | |||||||||
Income Tax Disclosure [Abstract] | ' | ||||||||
Income Taxes | ' | ||||||||
11 | Income Taxes | ||||||||
Due to our historical net loss position, and as we have recorded a full valuation allowance against net deferred tax assets, there is no provision or benefit for income taxes recorded for the years ended December 31, 2013 and 2012. | |||||||||
The income tax benefit is different from that which would be obtained by applying the statutory Federal income tax rate of 34% to income before income tax expense. The items causing this difference for the years ended December 31, 2013 and 2012 are as follows: | |||||||||
December 31, | |||||||||
2013 | 2012 | ||||||||
Income tax benefit at federal statutory rate | $ | (7,303,000 | ) | $ | (5,289,000 | ) | |||
R & D credit | (804,000 | ) | 279,000 | ||||||
Stock options | 207,000 | 205,000 | |||||||
Net operating loss adjustment | — | 14,433,000 | |||||||
Other | 37,000 | (20,000 | ) | ||||||
Change in federal valuation allowance | 7,863,000 | (9,608,000 | ) | ||||||
Total | $ | — | $ | — | |||||
Deferred income taxes reflect the net tax effect of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of deferred tax assets and liabilities at December 31, 2013 and 2012 are as follows: | |||||||||
December 31, | |||||||||
2013 | 2012 | ||||||||
Deferred tax assets: | |||||||||
Accrued expenses | $ | 170,969 | $ | 118,722 | |||||
Stock options expense under ASC 718 | 1,750,192 | 1,362,557 | |||||||
Net operating loss carry forwards | 12,993,615 | 6,098,125 | |||||||
Income tax credit carry forwards | 1,077,789 | 137,123 | |||||||
Property and equipment | 4,542 | 141,755 | |||||||
Intangibles | 1,124,264 | 2,288,961 | |||||||
Other | 19,946 | 20,110 | |||||||
Total deferred tax assets | 17,141,317 | 10,167,353 | |||||||
Less: valuation allowance | (17,141,317 | ) | (10,167,353 | ) | |||||
Total deferred tax assets, net of valuation allowance | $ | — | $ | — | |||||
Deferred tax liabilities: | |||||||||
Acquired intangibles | (2,608,755 | ) | (2,608,755 | ) | |||||
Total deferred tax assets/liabilities, net of valuation allowance | $ | (2,608,755 | ) | $ | (2,608,755 | ) | |||
We have established a full valuation allowance against our net deferred tax assets due to uncertainty surrounding the realization of such assets. Management has determined it is more likely than not that the deferred tax assets are not realizable due to our historical loss position. | |||||||||
As a result of our acquisition of SynthRx during 2011, we recorded a deferred tax liability. This deferred tax liability reflects the tax impact of the difference between the book basis and tax basis of acquired IPR&D that has not yet reached feasibility. Such deferred tax liability cannot be used to offset deferred tax assets when analyzing our end of year valuation allowance as the acquired IPR&D is considered to have an indefinite life until we complete or abandon development of MST-188. The deferred tax liability was recorded as an offset to goodwill recorded as part of the acquisition. | |||||||||
Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or IRC, limit our ability to use net operating loss carry forwards and R&D tax credit carry forwards (“tax attribute carry forwards”) to offset future taxable income or income tax, respectively, if we experience a cumulative change in ownership of more than 50% within a three-year testing period. During the first quarter of 2012, we completed a formal study through the year ended December 31, 2011 and determined ownership changes within the meaning of IRC Section 382 had occurred during 2010 and 2011, with the most recent as a result of our November 2011 common stock and warrant financing. As a result of these ownership changes, upon application of limitations prescribed by IRC Section 382, we are ineligible to utilize any of the tax attribute carry forwards we had accumulated as of November 11, 2011 to offset future taxable income, and we adjusted our tax attribute carry forwards and deferred tax assets accordingly. As the deferred tax assets associated with the tax attribute carry forwards accumulated as of November 11, 2011 were fully offset by a valuation allowance, a corresponding reduction in the Company’s valuation allowance was also recorded, resulting in no income tax impact. We have not yet conducted a formal study to determine whether an ownership change within the meaning of IRC Section 382 occurred during 2012 or 2013. However, we anticipate that our June 2013 common stock and warrant financing resulted in an ownership change within the meaning of IRC Section 382; therefore, we expect that we are ineligible to utilize any of the tax attribute carry forwards we had accumulated after November 11, 2011 and before June 19, 2013. If other ownership changes are identified, the amount of remaining tax attribute carry forwards available for utilization in future years may be further significantly reduced. However, because all deferred tax assets associated with such tax attribute carry forwards are fully offset by a valuation allowance any such reduction would have no income tax impact. | |||||||||
As of December 31, 2013, we had federal and California net operating loss carry forwards of $35.5 million and $16.0 million, respectively. These tax loss carry forwards begin to expire in 2031 if unused. As of December 31, 2013, we also had federal and gross California R&D tax credit carry forwards of $826,000 and $382,000, respectively. The federal R&D tax credits will begin to expire in 2031. The California R&D tax credits do not expire. We recognized our 2012 federal R&D tax credit in our financial statements for the year ended December 31, 2013 as legislation extending such credit was not enacted until 2013. | |||||||||
In accordance with authoritative guidance, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. As of December 31, 2013, we continue to have no unrecognized tax benefits. There are no unrecognized tax benefits included on the balance sheet that would, if recognized, impact the effective tax rate. We do not anticipate there will be a significant change in unrecognized tax benefits within the next 12 months. | |||||||||
Our policy is to recognize interest and/or penalties related to income tax matters in income tax expense. Because we have generated net operating losses since inception, no tax liability, penalties or interest has been recognized for balance sheet or income statement purposes as of and for the years ended December 31, 2013 and 2012. | |||||||||
We are subject to income taxation in the U.S. and the state of California. All of our tax years are subject to examination by the tax authorities due to the carry forward of unutilized net operating losses and R&D tax credits. |
401k_Plan
401(k) Plan | 12 Months Ended | |
Dec. 31, 2013 | ||
Compensation And Retirement Disclosure [Abstract] | ' | |
401(k) Plan | ' | |
12 | 401(k) Plan | |
We have a defined contribution savings plan pursuant to Section 401(k) of the IRC. The plan is for the benefit of all qualifying employees and permits voluntary contributions by employees up to 100% of eligible compensation, subject to the Internal Revenue Service (“IRS”) imposed maximum limits. The terms of the plan require us to make matching contributions equal to 100% of employee contributions up to 6% of eligible compensation, limited by the IRS-imposed maximum. We incurred total expenses of $182,416 and $163,171 in employer matching contributions in 2013 and 2012, respectively. |
Segment_Information
Segment Information | 12 Months Ended | |
Dec. 31, 2013 | ||
Segment Reporting [Abstract] | ' | |
Segment Information | ' | |
13 | Segment Information | |
We operate our business on the basis of a single reportable segment, which is the business of developing therapies for serious or life-threatening diseases. We evaluate our Company as a single operating segment. The majority of our operating activities and work performed by our employees are currently conducted from a single location in the U.S. We recognized no revenues in 2013 and 2012. |
Summary_of_Quarterly_Financial
Summary of Quarterly Financial Data (unaudited) | 12 Months Ended | ||||||||||||||||
Dec. 31, 2013 | |||||||||||||||||
Quarterly Financial Information Disclosure [Abstract] | ' | ||||||||||||||||
Summary of Quarterly Financial Data (unaudited) | ' | ||||||||||||||||
14 | Summary of Quarterly Financial Data (unaudited) | ||||||||||||||||
The following is a summary of the unaudited quarterly results of operations for the years ended December 31, 2013 and 2012: | |||||||||||||||||
Quarterly statements of operations data | |||||||||||||||||
Quarters Ended | |||||||||||||||||
2013 (unaudited): | 31-Mar | June 30 | September 30 | December 31 | |||||||||||||
Revenue | $ | — | $ | — | $ | — | $ | — | |||||||||
Loss from operations | (5,592,913 | ) | (4,953,239 | ) | (5,270,721 | ) | (5,722,328 | ) | |||||||||
Net loss | (5,580,867 | ) | (4,941,172 | ) | (5,253,531 | ) | (5,704,715 | ) | |||||||||
Net loss applicable to common stock | (5,580,867 | ) | (4,941,172 | ) | (5,253,531 | ) | (5.704,715 | ) | |||||||||
Basic and diluted net loss per share | $ | (0.12 | ) | $ | (0.09 | ) | $ | (0.05 | ) | $ | (0.06 | ) | |||||
Basic and diluted weighted average number of shares of common stock outstanding | 46,265,286 | 53,749,791 | 102,710,286 | 102,710,286 | |||||||||||||
Quarters Ended | |||||||||||||||||
2012 (unaudited): | 31-Mar | June 30 | September 30 | December 31 | |||||||||||||
Revenue | $ | — | $ | — | $ | — | $ | — | |||||||||
Loss from operations | (4,171,496 | ) | (4,221,558 | ) | (3,218,499 | ) | (4,016,449 | ) | |||||||||
Net loss | (4,152,517 | ) | (4,211,163 | ) | (3,199,053 | ) | (3,996,756 | ) | |||||||||
Net loss applicable to common stock | (4,152,517 | ) | (4,211,163 | ) | (3,199,053 | ) | (3,996,756 | ) | |||||||||
Basic and diluted net loss per share | $ | (0.09 | ) | $ | (0.09 | ) | $ | (0.07 | ) | $ | (0.08 | ) | |||||
Basic and diluted weighted average number of shares of common stock outstanding | 47,715,709 | 47,715,709 | 47,715,709 | 47,418,669 |
Subsequent_Events
Subsequent Events | 12 Months Ended | |
Dec. 31, 2013 | ||
Subsequent Events [Abstract] | ' | |
Subsequent Events | ' | |
15 | Subsequent Events | |
Acquisition of Aires Pharmaceuticals | ||
In February 2014, we completed the acquisition of Aires Pharmaceuticals, Inc., a development-stage, privately-held Delaware corporation, in an all-stock transaction pursuant to the terms of an agreement and plan of merger, dated February 7, 2014, by and among us, AP Acquisition Sub, Inc., a wholly-owned subsidiary of ours, Aires, and a stockholders’ representative (the “Merger Agreement”). Aires survived the merger transaction as a wholly-owned subsidiary of ours. Aires’ lead product candidate, AIR001 (sodium nitrite) inhalation solution, has orphan drug designation in the United States and European Union for the treatment of pulmonary arterial hypertension. | ||
Upon completion of the merger, we issued an aggregate of 1,049,706 unregistered shares of our common stock to former Aires stockholders and, following a six-month holdback period, we will issue up to 4,198,830 additional unregistered shares of our common stock, in the aggregate, to former Aires stockholders, subject to adjustment to satisfy indemnification obligations of the former Aires stockholders to us, if any, in accordance with the merger agreement. There are no milestone or earn-out payments under the merger agreement; therefore, the total merger consideration will not exceed 5,248,536 shares, or 5% of the shares of our common stock outstanding as of the closing date of the merger. | ||
We will account for the acquisition of Aires in accordance with ASC Topic 805. | ||
“At the Market” Equity Offering Program | ||
In February 2014, we entered into a sales agreement with Cowen and Company, LLC (“Cowen”), to sell shares of our common stock, with aggregate gross sales proceeds of up to $30 million, from time to time, through an “at the market” equity offering program (the “ATM program”), under which Cowen acts as sales agent. As of March 24, 2014, we had sold and issued an aggregate of 9,847,842 shares at a weighted-average sales price of $0.83 per share under the ATM program for aggregate gross proceeds of $8.2 million. After deducting sales agent commission and discounts, such proceeds totaled $8.0 million. |
Summary_of_Significant_Account1
Summary of Significant Accounting Policies (Policies) | 12 Months Ended | ||||||||||||
Dec. 31, 2013 | |||||||||||||
Accounting Policies [Abstract] | ' | ||||||||||||
Basis of Presentation | ' | ||||||||||||
Basis of Presentation | |||||||||||||
The consolidated financial statements include the accounts of Mast Therapeutics and its wholly-owned subsidiaries, SD Pharmaceuticals, Inc. (“SD Pharmaceuticals”) and SynthRx, Inc. (“SynthRx”). All intercompany accounts and transactions have been eliminated in consolidation. | |||||||||||||
We accounted for the acquisition of SynthRx in accordance with Accounting Standards Codification (“ASC”) Topic 805, Business Combinations (“ASC Topic 805”). ASC Topic 805 establishes principles and requirements for recognizing and measuring the total consideration transferred to and the assets acquired, liabilities assumed and any non-controlling interests in the acquired target in a business combination. ASC Topic 805 also provides guidance for recognizing and measuring goodwill acquired in a business combination; requires purchased in-process research and development (“IPR&D”) to be capitalized at fair value as an intangible asset at the time of acquisition; requires acquisition-related expenses and restructuring costs to be recognized separately from the business combination; expands the definition of what constitutes a business; and requires the acquirer to disclose information that users may need to evaluate and understand the financial effect of the business combination. | |||||||||||||
Use of Estimates | ' | ||||||||||||
Use of Estimates | |||||||||||||
The preparation of financial statements in conformity with United States generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates, including estimates related to IPR&D, goodwill, R&D expenses and share-based compensation expenses. We base our estimates on historical experience and various other relevant assumptions we believe to be reasonable under the circumstances. Actual results may differ from these estimates. | |||||||||||||
Fair Value of Financial Instruments | ' | ||||||||||||
Fair Value of Financial Instruments | |||||||||||||
Our investment securities are, and prior to its settlement our contingent liability was, carried at fair value (see Note 5). Cash equivalents, prepaid expenses and other current assets, accounts payable and accrued liabilities, are carried at cost, which we believe approximates fair value due to the short-term maturities of these instruments. | |||||||||||||
Cash Equivalents | ' | ||||||||||||
Cash Equivalents | |||||||||||||
We consider all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. Cash equivalents are carried at cost, which we believe approximates fair value due to the short-term maturities of these instruments. At December 31, 2013 and 2012, we had $1.3 million and $1.0 million of cash equivalents, respectively. | |||||||||||||
Investment Securities | ' | ||||||||||||
Investment Securities | |||||||||||||
Investment securities are marketable equity or debt securities. All of our investment securities are “available-for-sale” securities and carried at fair value (see Note 5). Fair value for securities with short maturities and infrequent secondary market trades typically is determined by using a curve-based evaluation model that utilizes quoted prices for similar securities. The evaluation model takes into consideration the days to maturity, coupon rate and settlement date convention. Net unrealized gains or losses on these securities are included in accumulated other comprehensive loss, which is a separate component of stockholders’ equity. Realized gains and realized losses are included in other income/(expense), while amortization of premiums and accretion of discounts are included in interest income. Interest and dividends on available-for-sale securities are included in interest income. We periodically evaluate our investment securities for impairment. If we determine that a decline in fair value of any investment security is other than temporary, then the cost basis would be written down to fair value and the decline in value would be charged to earnings. | |||||||||||||
Our investment securities are under the custodianship of a major financial institution and consist of FDIC-insured certificates of deposit. We have classified all of our available-for-sale investment securities, including those with maturities beyond one year from the date of purchase, as current assets on our consolidated balance sheets because we consider them to be highly liquid and available for use, if needed, in current operations. As of December 31, 2013, $2.9 million of our investment securities had contractual maturity dates of more than one year and less than or equal to 18 months and none were greater than 18 months. | |||||||||||||
Property and Equipment | ' | ||||||||||||
Property and Equipment | |||||||||||||
Property and equipment are stated at cost, less accumulated depreciation. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets (generally three to five years). Leasehold improvements are amortized over the economic life of the asset or the lease term, whichever is shorter. Repairs and maintenance are expensed as incurred. | |||||||||||||
In accordance with ASC Topic 360-10, Property, Plant and Equipment – Overall, we test for recoverability of long-lived assets, including property and equipment, if events or changes in circumstances indicate that the carrying amount for the assets may not be recoverable. If our assessment indicates impairment, we measure the impairment loss as the amount by which the carrying amount exceeds fair value of the assets. Fair value determinations are based on an undiscounted cash flow model, or independent appraisals, as appropriate. | |||||||||||||
Intangible Assets - Goodwill and Acquired In-Process Research & Development | ' | ||||||||||||
Intangible Assets – Goodwill and Acquired In-Process Research & Development | |||||||||||||
In accordance with ASC Topic 350, Intangibles – Goodwill and Other (“ASC Topic 350”), our goodwill and acquired IPR&D are determined to have indefinite lives and, therefore, are not amortized. Instead, they are tested for impairment annually and between annual tests if we become aware of an event or a change in circumstances that would indicate the carrying value may be impaired. We perform our annual impairment testing as of September 30 of each year. Pursuant to Accounting Standards Update, or ASU, No. 2011-08, Intangibles – Goodwill and Other (Topic 350): Testing Goodwill for Impairment, and No. 2012-02, Intangibles – Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment, we have the option to first assess qualitative factors to determine whether the existence of events or circumstances leads us to determine that it is more likely than not (that is, a likelihood of more than 50%) that our goodwill or our acquired IPR&D is impaired. If we choose to first assess qualitative factors and we determine that it is not more likely than not goodwill or acquired IPR&D is impaired, we are not required to take further action to test for impairment. We also have the option to bypass the qualitative assessment and perform only the quantitative impairment test, which we may choose to do in some periods but not in others. | |||||||||||||
In performing the quantitative assessment for goodwill, we utilize the two-step approach prescribed under ASC Topic 350. Step 1 requires a comparison of the carrying value of a reporting unit, including goodwill, to its estimated fair value. We test for impairment at the entity level because we operate on the basis of a single reporting unit. If our carrying value exceeds our fair value, we then perform Step 2 to measure the amount of impairment loss, if any. In Step 2, we estimate the fair value of our individual assets, including identifiable intangible assets, and liabilities to determine the implied fair value of goodwill. We then compare the carrying value of our goodwill to its implied fair value. The excess of the carrying value of goodwill over its implied fair value, if any, is recorded as an impairment charge. | |||||||||||||
In performing the quantitative assessment for acquired IPR&D, we compare the carrying value of acquired IPR&D to its estimated fair value. We calculate the estimated fair value of acquired IPR&D by using the Multi-Period Excess Earnings Method, or MPEEM, which is a form of the income approach. Under the MPEEM, the fair value of an intangible asset is equal to the present value of the asset’s incremental after-tax cash flows (excess earnings) remaining after deducting the market rates of return on the estimated value of contributory assets (contributory charge) over its remaining useful life. This method requires us to make long-term projections of revenues and expenses related to development and commercialization of the acquired assets and assumptions regarding the rate of return on contributory assets, the weighted average cost of capital and the probability adjustment factor for estimated future after-tax cash flows. The excess of the carrying value over its estimated fair value is recorded as an impairment charge. | |||||||||||||
All impairment charges are recorded to our consolidated statements of operations and comprehensive income/(loss). Our determinations as to whether, and, if so, the extent to which, goodwill and acquired IPR&D become impaired are highly judgmental and based on significant assumptions regarding our projected future financial condition and operating results, changes in the manner of our use and development of the acquired assets, our overall business strategy, and regulatory, market and economic environment and trends. We perform our annual impairment testing as of September 30 each year. As of September 30, 2013, no impairment of goodwill or acquired IPR&D was identified. | |||||||||||||
For acquisitions prior to January 1, 2009, the estimated fair value of acquired IPR&D was expensed immediately for projects that, as of the acquisition date, had not reached technological feasibility, had no alternative future use and had uncertainty in receiving future economic benefits from the acquired IPR&D. In the year ended December 31, 2006, we recorded $10.4 million of IPR&D expense related to our acquisition of SD Pharmaceuticals. | |||||||||||||
Concentration of Credit Risk and Significant Sources of Supply | ' | ||||||||||||
Concentration of Credit Risk and Significant Sources of Supply | |||||||||||||
Financial instruments that potentially subject us to concentrations of credit risk are primarily cash, cash equivalents and investment securities. We have a board-approved investment policy that sets our investment parameters and limitations with objectives of preserving principal and liquidity. Our cash and cash equivalent balances consist primarily of money market accounts under the custodianship of major financial institutions. Investment securities are invested in accordance with our investment policy. We do not have any financial instruments with off-balance-sheet risk of accounting loss. | |||||||||||||
We rely on single-source, third-party manufacturers and suppliers for production and supply of key components of our product candidates, and for production of the final drug products themselves. If these single-source, third-party manufacturers and suppliers are unable to continue providing a key component or the final drug products, the initiation or progress of any clinical studies of our product candidates may be severely impeded. | |||||||||||||
Foreign Currency | ' | ||||||||||||
Foreign Currency | |||||||||||||
Net foreign currency gains (losses) resulting from transactions in currencies other than the functional currency are included in other income (expense) in our consolidated statement of operations and comprehensive income/(loss). For the years ended December 31, 2013 and 2012, we recorded net foreign currency gains of less than $1,000 and $53,000 respectively. As of both December 31, 2013 and 2012, less than 1% of our total liabilities were denominated in currencies other than the U.S. dollar, which is our functional currency. | |||||||||||||
Research and Development Expense | ' | ||||||||||||
Research and Development Expense | |||||||||||||
R&D costs are charged to expense as incurred and include, but are not limited to, clinical and nonclinical study costs, research-related manufacturing and related costs, employee salaries and benefits, consulting services fees and share-based compensation cost. Clinical study costs include, but are not limited to, clinical research organization fees, investigator fees, site costs and, as applicable, comparator drug costs. Costs for certain R&D activities, such as research-related manufacturing and clinical studies, are recognized based on an evaluation of the percentage of work completed or the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, duration of the study and/or information provided to us by our vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid expenses or accrued R&D costs. | |||||||||||||
Advance payments to third parties, including nonrefundable amounts, for goods and services that will be used or rendered for future R&D activities are deferred and capitalized, then expensed as the services are performed or as the underlying goods are delivered. If we do not expect the services to be rendered or goods to be delivered, any remaining capitalized amounts for nonrefundable advance payments are charged to expense immediately. | |||||||||||||
Milestone payments that we make in connection with in-licensed technology or product candidates are expensed as incurred when there is uncertainty in receiving future economic benefits from the licensed technology or product candidates. We consider the future economic benefits from the licensed technology or product candidates to be uncertain until such licensed technology is incorporated into products that, or such product candidates, are approved for marketing by the FDA or when other significant risk factors are abated. For accounting purposes, management has viewed future economic benefits for all of our licensed technology or product candidates to be uncertain. | |||||||||||||
Share-Based Compensation | ' | ||||||||||||
Share-Based Compensation | |||||||||||||
Share-based compensation cost is measured at the grant date, based on the estimated fair value of the award using the Black-Scholes valuation model, and is recognized as expense over the vesting period on a straight-line basis. Share-based compensation expense recognized in the consolidated statements of operations for the years ended December 31, 2013 and 2012 is based on awards ultimately expected to vest and has been reduced for estimated forfeitures. This estimate will be revised in subsequent periods if actual forfeitures differ from those estimates. None of our outstanding share-based awards have market or performance conditions. | |||||||||||||
Patent Costs | ' | ||||||||||||
Patent Costs | |||||||||||||
Legal costs in connection with approved patents and patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. These costs are recorded as selling, general and administrative expenses in our consolidated statement of operations and comprehensive income/(loss). | |||||||||||||
Income Taxes | ' | ||||||||||||
Income Taxes | |||||||||||||
We account for income taxes and the related accounts under the liability method. Deferred tax assets and liabilities are determined based on the differences between the financial statement carrying amounts and the income tax basis of assets and liabilities. A valuation allowance is applied against any net deferred tax asset if, based on available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. | |||||||||||||
The tax effects from an uncertain tax position can be recognized in our consolidated financial statements only if the position is more likely than not of being sustained upon an examination by tax authorities. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. | |||||||||||||
We account for interest and penalties related to income tax matters, if any, in income tax expense. | |||||||||||||
Comprehensive Income/(Loss) | ' | ||||||||||||
Comprehensive Income/(Loss) | |||||||||||||
Comprehensive income or loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources, including foreign currency translation adjustments and unrealized gains and losses on marketable securities. We present comprehensive income/(loss) in our consolidated statement of operations and comprehensive income/(loss). | |||||||||||||
Net Loss per Common Share | ' | ||||||||||||
Net Loss per Common Share | |||||||||||||
Basic and diluted net loss per common share is calculated by dividing the net loss applicable to common stock for the periods presented by the weighted-average number of common shares outstanding during those periods, respectively, without consideration for outstanding common stock equivalents because their effect would have been anti-dilutive. Common stock equivalents are included in the calculation of diluted earnings per common share only if their effect is dilutive. For the years ended December 31, 2013 and 2012, our outstanding common stock equivalents consisted of options and warrants to purchase shares of our common stock. The weighted-average number of those common stock equivalents outstanding for each of the periods presented is set forth in the table below: | |||||||||||||
Years ended December 31, | |||||||||||||
2013 | 2012 | ||||||||||||
Warrants | 31,576,405 | 17,093,296 | |||||||||||
Options | 5,742,168 | 3,111,854 | |||||||||||
37,318,573 | 20,205,150 | ||||||||||||
Supplemental Cash Flow Information | ' | ||||||||||||
Supplemental Cash Flow Information | |||||||||||||
Years ended December 31, | Inception | ||||||||||||
(June 12, 1996) | |||||||||||||
through | |||||||||||||
2013 | 2012 | December 31, 2013 | |||||||||||
Supplemental disclosures of cash flow information: | |||||||||||||
Interest paid | $ | — | $ | — | $ | 180,719 | |||||||
Supplemental disclosures of non-cash investing and financing activities: | |||||||||||||
Issuance of warrants, common stock and preferred stock for: | |||||||||||||
Conversion of notes payable and accrued interest | — | — | 1,213,988 | ||||||||||
Prepaid services to consultants | — | — | 1,482,781 | ||||||||||
Conversion of preferred stock | — | — | 13,674 | ||||||||||
Acquisitions | — | — | 30,666,878 | ||||||||||
Issuance of common stock to pay dividends | — | — | 213,000 | ||||||||||
Issuance of common stock for milestone achievement | 250 | — | 250 | ||||||||||
Financial advisor services in conjunction with financings | — | — | 3,477,571 | ||||||||||
Underwriter commissions in conjunction with financings | — | — | 766,784 | ||||||||||
Acquisition of treasury stock in settlement of a claim | — | — | 34,737 | ||||||||||
Cancellation of treasury stock | — | — | (34,737 | ) | |||||||||
Assumptions of liabilities in acquisitions | — | — | 1,531,806 | ||||||||||
Fair value of contingent liabilities, net of contingent assets, recorded at acquisition date | — | — | 784,419 | ||||||||||
Acquisition of license agreement for long-term debt | — | — | 161,180 | ||||||||||
Unrealized loss/(gain) on investment securities | 18,544 | (104 | ) | 18,582 | |||||||||
Disposal of equipment in conjunction with settlement of a liability | 99,875 | — | 99,875 | ||||||||||
Cashless exercise of warrants | — | — | 4,312 | ||||||||||
Dividends accrued | — | — | 621,040 | ||||||||||
Trade asset converted to available-for-sale asset | — | — | 108,000 | ||||||||||
Dividends extinguished | — | — | 408,240 | ||||||||||
Trade payable converted to note payable | — | — | 83,948 | ||||||||||
Issuance of warrants for return of common stock | — | — | 50,852 | ||||||||||
Detachable warrants issued with notes payable | — | — | 450,000 | ||||||||||
Cumulative preferred stock dividends | — | — | 13,502,403 | ||||||||||
Recent Accounting Pronouncements | ' | ||||||||||||
Recent Accounting Pronouncements | |||||||||||||
In July 2013, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (“ASU 2013-11”). This standard requires an unrecognized tax benefit related to a net operating loss carryforward, a similar tax loss or a tax credit carryforward to be presented as a reduction to a deferred tax asset, unless the tax benefit is not available at the reporting date to settle any additional income taxes under the tax law of the applicable tax jurisdiction. ASU 2013-11 is effective for fiscal years and interim periods beginning after December 15, 2013, with early adoption permitted. We do not believe that the adoption of this standard will have an impact on our consolidated financial position, results of operations or cash flows. |
Summary_of_Significant_Account2
Summary of Significant Accounting Policies (Tables) | 12 Months Ended | ||||||||||||
Dec. 31, 2013 | |||||||||||||
Accounting Policies [Abstract] | ' | ||||||||||||
Weighted-Average Number of Common Stock Equivalents Outstanding | ' | ||||||||||||
The weighted-average number of those common stock equivalents outstanding for each of the periods presented is set forth in the table below: | |||||||||||||
Years ended December 31, | |||||||||||||
2013 | 2012 | ||||||||||||
Warrants | 31,576,405 | 17,093,296 | |||||||||||
Options | 5,742,168 | 3,111,854 | |||||||||||
37,318,573 | 20,205,150 | ||||||||||||
Supplemental Cash Flow Information | ' | ||||||||||||
Supplemental Cash Flow Information | |||||||||||||
Years ended December 31, | Inception | ||||||||||||
(June 12, 1996) | |||||||||||||
through | |||||||||||||
2013 | 2012 | December 31, 2013 | |||||||||||
Supplemental disclosures of cash flow information: | |||||||||||||
Interest paid | $ | — | $ | — | $ | 180,719 | |||||||
Supplemental disclosures of non-cash investing and financing activities: | |||||||||||||
Issuance of warrants, common stock and preferred stock for: | |||||||||||||
Conversion of notes payable and accrued interest | — | — | 1,213,988 | ||||||||||
Prepaid services to consultants | — | — | 1,482,781 | ||||||||||
Conversion of preferred stock | — | — | 13,674 | ||||||||||
Acquisitions | — | — | 30,666,878 | ||||||||||
Issuance of common stock to pay dividends | — | — | 213,000 | ||||||||||
Issuance of common stock for milestone achievement | 250 | — | 250 | ||||||||||
Financial advisor services in conjunction with financings | — | — | 3,477,571 | ||||||||||
Underwriter commissions in conjunction with financings | — | — | 766,784 | ||||||||||
Acquisition of treasury stock in settlement of a claim | — | — | 34,737 | ||||||||||
Cancellation of treasury stock | — | — | (34,737 | ) | |||||||||
Assumptions of liabilities in acquisitions | — | — | 1,531,806 | ||||||||||
Fair value of contingent liabilities, net of contingent assets, recorded at acquisition date | — | — | 784,419 | ||||||||||
Acquisition of license agreement for long-term debt | — | — | 161,180 | ||||||||||
Unrealized loss/(gain) on investment securities | 18,544 | (104 | ) | 18,582 | |||||||||
Disposal of equipment in conjunction with settlement of a liability | 99,875 | — | 99,875 | ||||||||||
Cashless exercise of warrants | — | — | 4,312 | ||||||||||
Dividends accrued | — | — | 621,040 | ||||||||||
Trade asset converted to available-for-sale asset | — | — | 108,000 | ||||||||||
Dividends extinguished | — | — | 408,240 | ||||||||||
Trade payable converted to note payable | — | — | 83,948 | ||||||||||
Issuance of warrants for return of common stock | — | — | 50,852 | ||||||||||
Detachable warrants issued with notes payable | — | — | 450,000 | ||||||||||
Cumulative preferred stock dividends | — | — | 13,502,403 |
Fair_Value_of_Financial_Instru1
Fair Value of Financial Instruments (Tables) | 12 Months Ended | ||||||||||||||||
Dec. 31, 2013 | |||||||||||||||||
Fair Value Disclosures [Abstract] | ' | ||||||||||||||||
Fair Values of Investment Securities and Contingent Liability | ' | ||||||||||||||||
The fair values at December 31, 2013 and 2012 of our investment securities and our contingent liability related to the SynthRx acquisition are summarized in the following tables: | |||||||||||||||||
December 31, 2013 | |||||||||||||||||
Total Fair | Fair Value Determined Under: | ||||||||||||||||
Value | (Level 1) | (Level 2) | (Level 3) | ||||||||||||||
Investment securities | $ | 18,711,448 | $ | — | $ | 18,711,448 | $ | — | |||||||||
Contingent liability | $ | — | $ | — | $ | — | $ | — | |||||||||
December 31, 2012 | |||||||||||||||||
Total Fair | Fair Value Determined Under: | ||||||||||||||||
Value | (Level 1) | (Level 2) | (Level 3) | ||||||||||||||
Investment securities | $ | 14,010,962 | $ | — | $ | 14,010,962 | $ | — | |||||||||
Contingent liability | $ | (142,500 | ) | $ | — | $ | — | $ | (142,500 | ) | |||||||
Class Reconciliation of the Contingent Liability That are Measured and Recorded at Fair Value on a Recurring Basis Using Significant Unobservable Inputs | ' | ||||||||||||||||
A reconciliation of the contingent liability that was measured and recorded at fair value on a recurring basis using significant unobservable inputs (Level 3) in the year ended December 31, 2013 until it was settled on May 30, 2013 is as follows: | |||||||||||||||||
Year ended December 31, 2013 | |||||||||||||||||
Contingent Liability | |||||||||||||||||
Beginning balance | $ | (142,500 | ) | ||||||||||||||
Settlement on May 30, 2013 | 177,500 | ||||||||||||||||
Total net unrealized losses included in earnings | (35,000 | ) | |||||||||||||||
Ending balance | $ | — | |||||||||||||||
Change in unrealized losses for the period included in earnings for assets or liabilities held during 2013 | $ | (35,000 | ) | ||||||||||||||
Property_and_Equipment_Tables
Property and Equipment (Tables) | 12 Months Ended | ||||||||||
Dec. 31, 2013 | |||||||||||
Property Plant And Equipment [Abstract] | ' | ||||||||||
Property and Equipment | ' | ||||||||||
Property and equipment at December 31, 2013 and 2012 were as follows: | |||||||||||
Useful Lives | 2013 | 2012 | |||||||||
Office furniture, computer and lab equipment | 3 - 5 years | $ | 275,035 | $ | 421,494 | ||||||
Computer software | 3 years | 57,526 | 62,509 | ||||||||
Leasehold improvements | 1 year | 34,900 | 34,900 | ||||||||
Equipment in progress | n/a | — | — | ||||||||
367,461 | 518,903 | ||||||||||
Less accumulated depreciation and amortization | (261,714 | ) | (320,545 | ) | |||||||
Property and equipment, net | $ | 105,747 | $ | 198,358 | |||||||
Accrued_Liabilities_Tables
Accrued Liabilities (Tables) | 12 Months Ended | ||||||||
Dec. 31, 2013 | |||||||||
Payables And Accruals [Abstract] | ' | ||||||||
Accrued Liabilities | ' | ||||||||
Accrued liabilities at December 31, 2013 and 2012 were as follows: | |||||||||
2013 | 2012 | ||||||||
Accrued R&D agreement and study expenses | $ | 2,273,860 | $ | 1,203,808 | |||||
Accrued acquisition costs | 44,640 | — | |||||||
Other accrued liabilities | 176,588 | 80,168 | |||||||
Accrued liabilities | $ | 2,495,088 | $ | 1,283,976 | |||||
Capital_Stock_and_Warrants_Tab
Capital Stock and Warrants (Tables) | 12 Months Ended | ||||||||
Dec. 31, 2013 | |||||||||
Equity [Abstract] | ' | ||||||||
Outstanding Warrants to Purchase Shares of Common Stock | ' | ||||||||
At December 31, 2013, outstanding warrants to purchase shares of common stock are as follows: | |||||||||
Warrants | Exercise Price | Expiration Date | |||||||
99,696 | $ | 11.9125 | Jun-14 | ||||||
144,000 | $ | 5.875 | Oct-14 | ||||||
19,007 | $ | 4.475 | Jul-14 | ||||||
14,183 | $ | 4.0625 | Aug-14 | ||||||
36,071 | $ | 3.75 | Jun-14 | ||||||
216,000 | $ | 3.67 | October 2014 | ||||||
1,816,608 | $ | 3.65 | May-15 | ||||||
409,228 | $ | 3.44 | Apr-15 | ||||||
2,046,139 | $ | 2.75 | Jan-16 | ||||||
1,062,500 | $ | 1 | Apr-15 | ||||||
10,625,000 | $ | 1.1 | November 2016 | ||||||
28,097,500 | $ | 0.65 | Jun-18 | ||||||
44,585,932 | |||||||||
Equity_Incentive_Plans_Tables
Equity Incentive Plans (Tables) | 12 Months Ended | ||||||||||||||||
Dec. 31, 2013 | |||||||||||||||||
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | ' | ||||||||||||||||
Share-Based Compensation Expense from All Stock Options Granted Charged to Consolidated Statements of Operations | ' | ||||||||||||||||
The share-based compensation expense from all stock options granted that has been charged to our consolidated statements of operations and comprehensive income/(loss) in those periods was as follows: | |||||||||||||||||
Years Ended December 31, | |||||||||||||||||
2013 | 2012 | ||||||||||||||||
Selling, general and administrative expense | $ | 1,428,437 | $ | 1,381,554 | |||||||||||||
Research and development expense | 171,385 | 77,776 | |||||||||||||||
Share-based compensation expense | $ | 1,599,822 | $ | 1,459,330 | |||||||||||||
Summary of Option Activity | ' | ||||||||||||||||
A summary of all of our option activity as of December 31, 2013 and 2012 and of changes in options outstanding under the plans during the year ended December 31, 2013 is as follows: | |||||||||||||||||
Shares | Weighted- | Weighted- | Aggregate | ||||||||||||||
Underlying | Average | Average | Intrinsic | ||||||||||||||
Options | Exercise | Remaining | Value | ||||||||||||||
Price | Contractual | ||||||||||||||||
Years | |||||||||||||||||
Outstanding at January 1, 2013 | 3,585,743 | $ | 2.31 | ||||||||||||||
Granted | 3,946,204 | $ | 0.51 | ||||||||||||||
Exercised | — | $ | — | ||||||||||||||
Cancelled/forfeited/expired | (227,119 | ) | $ | 0.88 | |||||||||||||
Outstanding at December 31, 2013 | 7,304,828 | $ | 1.38 | 8.57 | $ | 4,517 | |||||||||||
Options exercisable at December 31, 2013 | 2,471,671 | $ | 2.56 | 7.77 | $ | — | |||||||||||
Vested and expected to vest at December 31, 2013 | 7,197,119 | $ | 1.39 | 8.56 | $ | 3,710 | |||||||||||
Black-Scholes Option-Valuation Model and the Calculation of Share-based Compensation for Option Grants to Employees and Non-Employee Directors | ' | ||||||||||||||||
The assumptions used in the Black-Scholes option-valuation model and the calculation of share-based compensation for option grants to employees and non-employee directors during the years ended December 31, 2013 and 2012 are as follows: | |||||||||||||||||
Years Ended December 31, | |||||||||||||||||
2013 | 2012 | ||||||||||||||||
Risk-free interest rate | 1.0 - 2.0 | % | 0.6 - 0.8 | % | |||||||||||||
Dividend yield | 0 | % | 0 | % | |||||||||||||
Expected volatility | 113 - 132 | % | 131 - 139 | % | |||||||||||||
Expected term (in years) | 5.3 - 6.1 years | 5.2 - 6.1 years | |||||||||||||||
Forfeiture rate (officers and directors) | 0 | % | 0 - 4 | % | |||||||||||||
Forfeiture rate (employees) | 10 | % | 4 | % |
Commitments_Tables
Commitments (Tables) | 12 Months Ended | ||||
Dec. 31, 2013 | |||||
Commitments And Contingencies Disclosure [Abstract] | ' | ||||
Future Rental Commitments | ' | ||||
Future rental commitments under all operating leases are as follows: | |||||
Year Ending December 31, | |||||
2014 | 327,638 | ||||
2015 | 27,365 | ||||
2016 | — | ||||
2017 | — | ||||
2018 | — | ||||
Total | $ | 355,003 | |||
Income_Taxes_Tables
Income Taxes (Tables) | 12 Months Ended | ||||||||
Dec. 31, 2013 | |||||||||
Income Tax Disclosure [Abstract] | ' | ||||||||
Income Tax Provision/(Benefit) | ' | ||||||||
The income tax benefit is different from that which would be obtained by applying the statutory Federal income tax rate of 34% to income before income tax expense. The items causing this difference for the years ended December 31, 2013 and 2012 are as follows: | |||||||||
December 31, | |||||||||
2013 | 2012 | ||||||||
Income tax benefit at federal statutory rate | $ | (7,303,000 | ) | $ | (5,289,000 | ) | |||
R & D credit | (804,000 | ) | 279,000 | ||||||
Stock options | 207,000 | 205,000 | |||||||
Net operating loss adjustment | — | 14,433,000 | |||||||
Other | 37,000 | (20,000 | ) | ||||||
Change in federal valuation allowance | 7,863,000 | (9,608,000 | ) | ||||||
Total | $ | — | $ | — | |||||
Significant Components of Deferred Tax Assets and Liabilities | ' | ||||||||
Significant components of deferred tax assets and liabilities at December 31, 2013 and 2012 are as follows: | |||||||||
December 31, | |||||||||
2013 | 2012 | ||||||||
Deferred tax assets: | |||||||||
Accrued expenses | $ | 170,969 | $ | 118,722 | |||||
Stock options expense under ASC 718 | 1,750,192 | 1,362,557 | |||||||
Net operating loss carry forwards | 12,993,615 | 6,098,125 | |||||||
Income tax credit carry forwards | 1,077,789 | 137,123 | |||||||
Property and equipment | 4,542 | 141,755 | |||||||
Intangibles | 1,124,264 | 2,288,961 | |||||||
Other | 19,946 | 20,110 | |||||||
Total deferred tax assets | 17,141,317 | 10,167,353 | |||||||
Less: valuation allowance | (17,141,317 | ) | (10,167,353 | ) | |||||
Total deferred tax assets, net of valuation allowance | $ | — | $ | — | |||||
Deferred tax liabilities: | |||||||||
Acquired intangibles | (2,608,755 | ) | (2,608,755 | ) | |||||
Total deferred tax assets/liabilities, net of valuation allowance | $ | (2,608,755 | ) | $ | (2,608,755 | ) | |||
Summary_of_Quarterly_Financial1
Summary of Quarterly Financial Data (unaudited) (Tables) | 12 Months Ended | ||||||||||||||||
Dec. 31, 2013 | |||||||||||||||||
Quarterly Financial Information Disclosure [Abstract] | ' | ||||||||||||||||
Quarterly Statements of Operations Data | ' | ||||||||||||||||
The following is a summary of the unaudited quarterly results of operations for the years ended December 31, 2013 and 2012: | |||||||||||||||||
Quarterly statements of operations data | |||||||||||||||||
Quarters Ended | |||||||||||||||||
2013 (unaudited): | 31-Mar | June 30 | September 30 | December 31 | |||||||||||||
Revenue | $ | — | $ | — | $ | — | $ | — | |||||||||
Loss from operations | (5,592,913 | ) | (4,953,239 | ) | (5,270,721 | ) | (5,722,328 | ) | |||||||||
Net loss | (5,580,867 | ) | (4,941,172 | ) | (5,253,531 | ) | (5,704,715 | ) | |||||||||
Net loss applicable to common stock | (5,580,867 | ) | (4,941,172 | ) | (5,253,531 | ) | (5.704,715 | ) | |||||||||
Basic and diluted net loss per share | $ | (0.12 | ) | $ | (0.09 | ) | $ | (0.05 | ) | $ | (0.06 | ) | |||||
Basic and diluted weighted average number of shares of common stock outstanding | 46,265,286 | 53,749,791 | 102,710,286 | 102,710,286 | |||||||||||||
Quarters Ended | |||||||||||||||||
2012 (unaudited): | 31-Mar | June 30 | September 30 | December 31 | |||||||||||||
Revenue | $ | — | $ | — | $ | — | $ | — | |||||||||
Loss from operations | (4,171,496 | ) | (4,221,558 | ) | (3,218,499 | ) | (4,016,449 | ) | |||||||||
Net loss | (4,152,517 | ) | (4,211,163 | ) | (3,199,053 | ) | (3,996,756 | ) | |||||||||
Net loss applicable to common stock | (4,152,517 | ) | (4,211,163 | ) | (3,199,053 | ) | (3,996,756 | ) | |||||||||
Basic and diluted net loss per share | $ | (0.09 | ) | $ | (0.09 | ) | $ | (0.07 | ) | $ | (0.08 | ) | |||||
Basic and diluted weighted average number of shares of common stock outstanding | 47,715,709 | 47,715,709 | 47,715,709 | 47,418,669 |
Summary_of_Significant_Account3
Summary of Significant Accounting Policies - Additional Information (Detail) (USD $) | 12 Months Ended | 211 Months Ended | ||
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2006 | Dec. 31, 2013 | |
Summary Of Significant Accounting Policies [Line Items] | ' | ' | ' | ' |
Cash equivalents carried at cost | $1,300,000 | $1,000,000 | ' | $1,300,000 |
Cash and cash equivalents of highly liquid investments with maturity date of purchase | 'Three months or less | ' | ' | ' |
Amount of Investment Securities | 2,900,000 | ' | ' | 2,900,000 |
Determination percentage | 50.00% | ' | ' | ' |
In-process research and development | ' | ' | 10,400,000 | 10,422,130 |
Foreign currency gains | $1,000 | $53,000 | ' | ' |
Liabilities denominated in other currencies | 1.00% | 1.00% | ' | ' |
Uncertain income tax position | 50.00% | ' | ' | ' |
Minimum [Member] | ' | ' | ' | ' |
Summary Of Significant Accounting Policies [Line Items] | ' | ' | ' | ' |
Maturity period | '1 year | ' | ' | ' |
Estimated useful lives of assets | '3 years | ' | ' | ' |
Maximum [Member] | ' | ' | ' | ' |
Summary Of Significant Accounting Policies [Line Items] | ' | ' | ' | ' |
Maturity period | '18 months | ' | ' | ' |
Estimated useful lives of assets | '5 years | ' | ' | ' |
Summary_of_Significant_Account4
Summary of Significant Accounting Policies - Weighted-Average Number of Common Stock Equivalents Outstanding (Detail) | 12 Months Ended | |
Dec. 31, 2013 | Dec. 31, 2012 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ' | ' |
Anti-dilutive securities | 37,318,573 | 20,205,150 |
Warrants [Member] | ' | ' |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ' | ' |
Anti-dilutive securities | 31,576,405 | 17,093,296 |
Options [Member] | ' | ' |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ' | ' |
Anti-dilutive securities | 5,742,168 | 3,111,854 |
Summary_of_Significant_Account5
Summary of Significant Accounting Policies - Supplemental Cash Flow Information (Detail) (USD $) | 12 Months Ended | 211 Months Ended | |
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | |
Supplemental disclosures of cash flow information: | ' | ' | ' |
Interest paid | ' | ' | $180,719 |
Issuance of warrants, common stock and preferred stock for: | ' | ' | ' |
Conversion of notes payable and accrued interest | ' | ' | 1,213,988 |
Prepaid services to consultants | ' | ' | 1,482,781 |
Conversion of preferred stock | ' | ' | 13,674 |
Acquisitions | ' | ' | 30,666,878 |
Issuance of common stock to pay dividends | ' | ' | 213,000 |
Issuance of common stock for milestone achievement | 250 | ' | 250 |
Financial advisor services in conjunction with financings | ' | ' | 3,477,571 |
Underwriter commissions in conjunction with financings | ' | ' | 766,784 |
Acquisition of treasury stock in settlement of a claim | ' | ' | 34,737 |
Cancellation of treasury stock | ' | ' | -34,737 |
Assumptions of liabilities in acquisitions | ' | ' | 1,531,806 |
Fair value of contingent liabilities, net of contingent assets, recorded at acquisition date | ' | ' | 784,419 |
Acquisition of license agreement for long-term debt | ' | ' | 161,180 |
Unrealized loss/(gain) on investment securities | 18,544 | -104 | 18,582 |
Disposal of equipment in conjunction with settlement of a liability | 99,875 | ' | 99,875 |
Cashless exercise of warrants | ' | ' | 4,312 |
Dividends accrued | ' | ' | 621,040 |
Trade asset converted to available-for-sale asset | ' | ' | 108,000 |
Dividends extinguished | ' | ' | 408,240 |
Trade payable converted to note payable | ' | ' | 83,948 |
Issuance of warrants for return of common stock | ' | ' | 50,852 |
Detachable warrants issued with notes payable | ' | ' | 450,000 |
Cumulative preferred stock dividends | ' | ' | $13,502,403 |
Acquisition_of_SynthRx_Additio
Acquisition of SynthRx - Additional Information (Detail) (USD $) | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | |||||||
Dec. 31, 2013 | Dec. 31, 2012 | Apr. 08, 2011 | Jun. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Apr. 30, 2011 | Dec. 31, 2013 | Jun. 30, 2013 | Apr. 30, 2011 | Apr. 30, 2011 | Jun. 30, 2013 | Jun. 30, 2013 | |
SynthRx [Member] | SynthRx [Member] | SynthRx [Member] | First Milestone - Dosing of First Patient [Member] | First Milestone - Dosing of First Patient [Member] | First Milestone - Dosing of First Patient [Member] | Initial Consideration (Fully Vested Shares) [Member] | Initial Consideration (Subject to Vesting Shares) [Member] | Second Milestone - FDA Acceptance [Member] | Third Milestone - FDA Approval [Member] | ||||
Senior Vice President, Development [Member] | SynthRx [Member] | ||||||||||||
Business Acquisition, Equity Interests Issued or Issuable [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Minimum shares issued based on the achievement of First Milestone | 250,000 | ' | ' | ' | ' | ' | ' | ' | ' | 862,078 | ' | ' | ' |
Shares issued, subject to vesting shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,938,773 | ' | ' |
Percentage of shares issuable to reduce | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 75.00% | ' | ' |
Repurchase of shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,454,079 | ' | ' |
Repurchase price of shares | ' | ' | ' | ' | $0.00 | ' | $0.00 | ' | ' | ' | ' | ' | ' |
Additional Common stock shares issued | ' | ' | ' | 12,478,050 | ' | 52,543 | ' | 250,000 | 250,000 | ' | ' | ' | ' |
Shares issued , fully vested shares | ' | ' | ' | ' | ' | ' | ' | 1,000,000 | ' | ' | ' | 3,839,400 | 8,638,650 |
Preliminary estimated purchase price | ' | ' | $6,700,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
IPR & D, ANX-188 lead product program, fair value | ' | ' | ' | ' | 6,500,000 | ' | ' | ' | ' | ' | ' | ' | ' |
Goodwill | 3,006,883 | 3,006,883 | ' | ' | 3,000,000 | ' | ' | ' | ' | ' | ' | ' | ' |
Deferred income tax liability resulting from the acquisition | 2,600,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Subsequent re-measurement | ' | ' | ' | ' | ' | ' | ' | 0 | ' | ' | ' | ' | ' |
Net cash settlement provision | $0 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Investment_Securities_Addition
Investment Securities - Additional Information (Detail) (USD $) | 12 Months Ended | |
Dec. 31, 2013 | Dec. 31, 2012 | |
Investment Holdings [Abstract] | ' | ' |
Investment securities | $18,711,448 | $14,010,962 |
Cost basis of investments securities | 18,730,030 | ' |
Unrealized losses | $18,582 | ' |
Fair_Value_of_Financial_Instru2
Fair Value of Financial Instruments - Fair Values of Investments Securities and Contingent Liability (Detail) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items] | ' | ' |
Investment securities | $18,711,448 | $14,010,962 |
Contingent liability | ' | -142,500 |
Fair Value Determined Under Level 1 [Member] | ' | ' |
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items] | ' | ' |
Investment securities | ' | ' |
Contingent liability | ' | ' |
Fair Value Determined Under Level 2 [Member] | ' | ' |
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items] | ' | ' |
Investment securities | 18,711,448 | 14,010,962 |
Contingent liability | ' | ' |
Fair Value Determined Under Level 3 [Member] | ' | ' |
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items] | ' | ' |
Investment securities | ' | ' |
Contingent liability | ' | ($142,500) |
Fair_Value_of_Financial_Instru3
Fair Value of Financial Instruments - Reconciliation of the Contingent Asset and Liability that are Measured and Recorded at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Detail) (USD $) | 12 Months Ended |
Dec. 31, 2013 | |
Fair Value Disclosures [Abstract] | ' |
Beginning balance | ($142,500) |
Settlement on May 30, 2013 | 177,500 |
Total net unrealized losses included in earnings | -35,000 |
Ending balance | ' |
Change in unrealized losses for the period included in earnings for assets or liabilities held during 2013 | ($35,000) |
Property_and_Equipment_Propert
Property and Equipment - Property and Equipment (Detail) (USD $) | 12 Months Ended | |
Dec. 31, 2013 | Dec. 31, 2012 | |
Property, Plant and Equipment [Line Items] | ' | ' |
Property and equipment, gross | $367,461 | $518,903 |
Less accumulated depreciation and amortization | -261,714 | -320,545 |
Property and equipment, net | 105,747 | 198,358 |
Minimum [Member] | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Useful Lives | '3 years | ' |
Maximum [Member] | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Useful Lives | '5 years | ' |
Office Furniture, Computer and Lab Equipment [Member] | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Property and equipment, gross | 275,035 | 421,494 |
Office Furniture, Computer and Lab Equipment [Member] | Minimum [Member] | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Useful Lives | '3 years | ' |
Office Furniture, Computer and Lab Equipment [Member] | Maximum [Member] | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Useful Lives | '5 years | ' |
Computer Software [Member] | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Useful Lives | '3 years | ' |
Property and equipment, gross | 57,526 | 62,509 |
Leasehold Improvements [Member] | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Useful Lives | '1 year | ' |
Property and equipment, gross | 34,900 | 34,900 |
Equipment in progress [Member] | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Property and equipment, gross | ' | ' |
Property_and_Equipment_Additio
Property and Equipment - Additional Information (Detail) (USD $) | 1 Months Ended | 12 Months Ended | 211 Months Ended | |
Apr. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | |
Property, Plant and Equipment [Line Items] | ' | ' | ' | ' |
Depreciation and amortization expense | ' | $39,517 | $90,047 | $10,614,754 |
Original of cost equipment | ' | 367,461 | 518,903 | 367,461 |
Impairment loss | ' | ' | 402,739 | 510,739 |
wrote-off the carrying amount | 99,875 | ' | ' | ' |
Equipment [Member] | ' | ' | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' | ' | ' |
Original of cost equipment | ' | ' | $600,000 | ' |
Accrued_Liabilities_Accrued_Li
Accrued Liabilities - Accrued Liabilities (Detail) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
Payables And Accruals [Abstract] | ' | ' |
Accrued R&D agreement and study expenses | $2,273,860 | $1,203,808 |
Accrued acquisition costs | 44,640 | ' |
Other accrued liabilities | 176,588 | 80,168 |
Total accrued liabilities | $2,495,088 | $1,283,976 |
Capital_Stock_and_Warrants_Add
Capital Stock and Warrants - Additional Information (Detail) (USD $) | 1 Months Ended | ||
In Millions, except Share data, unless otherwise specified | Jun. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 |
Class of Warrant or Right [Line Items] | ' | ' | ' |
Common stock, shares authorized | ' | 500,000,000 | 500,000,000 |
Common stock, par value | ' | $0.00 | $0.00 |
Preferred stock, authorized | ' | 1,000,000 | ' |
Preferred stock, par value | ' | $0.00 | ' |
Common stock, shares outstanding | ' | 102,710,286 | 46,265,286 |
Preferred stock, shares outstanding | ' | 0 | ' |
Common stock, shares issued | 56,195,000 | ' | ' |
Additional shares of common stock purchased using warrants | 28,097,500 | ' | ' |
Treasury stock issued | 1,454,079 | ' | ' |
Securities offered and sold combination | 'These securities were offered and sold to the underwriters and the public in units with each unit consisting of one share of common stock and one warrant to purchase up to 0.5 of a share of common stock. | ' | ' |
Aggregate number of common stock | 0.5 | ' | ' |
Gross proceeds of financing | $28.10 | ' | ' |
Additional proceeds from the exercise of warrants | 18.3 | ' | ' |
Net proceeds from financing | $25.70 | ' | ' |
Warrants exercisable | 19-Jun-18 | ' | ' |
Warrants [Member] | ' | ' | ' |
Class of Warrant or Right [Line Items] | ' | ' | ' |
Exercise price of warrants per share | 0.65 | ' | ' |
Capital_Stock_and_Warrants_Out
Capital Stock and Warrants - Outstanding Warrants to Purchase Shares of Common Stock (Detail) | 12 Months Ended |
Dec. 31, 2013 | |
Class of Warrant or Right [Line Items] | ' |
Shares Underlying Outstanding Warrants | 44,585,932 |
June 2014 [Member] | ' |
Class of Warrant or Right [Line Items] | ' |
Shares Underlying Outstanding Warrants | 99,696 |
Exercise Price | 11.9125 |
Expiration Date | '2014-06 |
October 2014 [Member] | ' |
Class of Warrant or Right [Line Items] | ' |
Shares Underlying Outstanding Warrants | 144,000 |
Exercise Price | 5.875 |
Expiration Date | '2014-10 |
July 2014 [Member] | ' |
Class of Warrant or Right [Line Items] | ' |
Shares Underlying Outstanding Warrants | 19,007 |
Exercise Price | 4.475 |
Expiration Date | '2014-07 |
August 2014 [Member] | ' |
Class of Warrant or Right [Line Items] | ' |
Shares Underlying Outstanding Warrants | 14,183 |
Exercise Price | 4.0625 |
Expiration Date | '2014-08 |
June 2014 [Member] | ' |
Class of Warrant or Right [Line Items] | ' |
Shares Underlying Outstanding Warrants | 36,071 |
Exercise Price | 3.75 |
Expiration Date | '2014-06 |
October 2014 [Member] | ' |
Class of Warrant or Right [Line Items] | ' |
Shares Underlying Outstanding Warrants | 216,000 |
Exercise Price | 3.67 |
Expiration Date | '2014-10 |
May 2015 [Member] | ' |
Class of Warrant or Right [Line Items] | ' |
Shares Underlying Outstanding Warrants | 1,816,608 |
Exercise Price | 3.65 |
Expiration Date | '2015-05 |
April 2015 [Member] | ' |
Class of Warrant or Right [Line Items] | ' |
Shares Underlying Outstanding Warrants | 409,228 |
Exercise Price | 3.44 |
Expiration Date | '2015-04 |
January 2016 [Member] | ' |
Class of Warrant or Right [Line Items] | ' |
Shares Underlying Outstanding Warrants | 2,046,139 |
Exercise Price | 2.75 |
Expiration Date | '2016-01 |
April 2015 [Member] | ' |
Class of Warrant or Right [Line Items] | ' |
Shares Underlying Outstanding Warrants | 1,062,500 |
Exercise Price | 1 |
Expiration Date | '2015-04 |
November 2016 [Member] | ' |
Class of Warrant or Right [Line Items] | ' |
Shares Underlying Outstanding Warrants | 10,625,000 |
Exercise Price | 1.1 |
Expiration Date | '2016-11 |
June 2018 [Member] | ' |
Class of Warrant or Right [Line Items] | ' |
Shares Underlying Outstanding Warrants | 28,097,500 |
Exercise Price | 0.65 |
Expiration Date | '2018-06 |
Equity_Incentive_Plans_ShareBa
Equity Incentive Plans - Share-Based Compensation Expense from All Stock Options Granted Charged to Consolidated Statements of Operations (Detail) (USD $) | 12 Months Ended | |
Dec. 31, 2013 | Dec. 31, 2012 | |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' |
Share-based compensation expense | $1,599,822 | $1,459,330 |
Selling, General and Administrative Expense [Member] | ' | ' |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' |
Share-based compensation expense | 1,428,437 | 1,381,554 |
Research and Development Expense [Member] | ' | ' |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' |
Share-based compensation expense | $171,385 | $77,776 |
Equity_Incentive_Plans_Additio
Equity Incentive Plans - Additional Information (Detail) (USD $) | 12 Months Ended | |
In Millions, except Share data, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' |
Common stock available for grant | 3,251,222 | ' |
Purchase price of shares of common stock | 'Less than 100% | ' |
Contractual term | '10 years | ' |
Vesting period | '4 years | ' |
Options exercisable, cancelled | 227,119 | 236,729 |
Weighted-average grant date fair value | $0.41 | $0.61 |
Unamortized compensation cost | $2.60 | ' |
Expected to be recognized over a weighted-average period | '2 years 8 months 23 days | ' |
Percentage lower of fair market value at which employees are eligible to purchase common stock | 85.00% | ' |
Percentage of employee compensation authorized to withhold | 15.00% | ' |
Common stock issued under purchase plan | 276,945 | ' |
Percentage of common stock subject to annual automatic increase | 1.00% | ' |
Common stock subject to annual automatic increase | 30,000 | ' |
Options [Member] | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' |
Stock appreciation right | 1 | ' |
Other Than Stock Option [Member] | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' |
Stock appreciation right | 1.5 | ' |
2005 Equity Incentive Plan [Member] | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' |
Awards granted | 0 | ' |
2008 Omnibus Incentive Plan [Member] | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' |
Awards granted | 0 | ' |
Original 2008 Plan [Member] | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' |
Awards granted | 0 | ' |
Amended and Restated 2008 Plan [Member] | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' |
Awards granted | 0 | ' |
Equity_Incentive_Plans_Summary
Equity Incentive Plans - Summary of Option Activity (Detail) (USD $) | 12 Months Ended | |
Dec. 31, 2013 | Dec. 31, 2012 | |
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | ' | ' |
Shares Underlying Options, Outstanding at beginning balance | 3,585,743 | ' |
Shares Underlying Options, Granted | 3,946,204 | ' |
Shares Underlying Options, Exercised | ' | ' |
Shares Underlying Options, Cancelled/Forfeited/Expired | -227,119 | -236,729 |
Shares Underlying Options, Outstanding at ending balance | 7,304,828 | 3,585,743 |
Shares Underlying Options, Options exercisable | 2,471,671 | ' |
Shares Underlying Options, Vested and expected to vest | 7,197,119 | ' |
Weighted average exercise price, beginning balance | $2.31 | ' |
Weighted average exercise price, Granted | $0.51 | ' |
Weighted average exercise price, Exercised | ' | ' |
Weighted average exercise price, Cancelled/Forfeited/Expired | $0.88 | ' |
Weighted average exercise price, ending balance | $1.38 | $2.31 |
Weighted average exercise price, Options exercisable | $2.56 | ' |
Weighted average exercise price, Vested and expected to vest | $1.39 | ' |
Weighted average remaining contractual years, beginning balance | '8 years 6 months 26 days | ' |
Weighted average remaining contractual years, Option exercisable | '7 years 9 months 7 days | ' |
Weighted average remaining contractual years, Vested and expected to vest | '8 years 6 months 22 days | ' |
Aggregate intrinsic value, beginning balance | ' | ' |
Aggregate intrinsic value, ending balance | 4,517 | ' |
Aggregate intrinsic value, Options exercisable | ' | ' |
Aggregate intrinsic value, Vested and expected to vest | $3,710 | ' |
Equity_Incentive_Plans_BlackSc
Equity Incentive Plans - Black-Scholes Option-Valuation Model for Option Grants to Employees and Non-Employee Directors (Detail) | 12 Months Ended | |
Dec. 31, 2013 | Dec. 31, 2012 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' |
Dividend yield | 0.00% | 0.00% |
Forfeiture rate (officers and directors) | 0.00% | ' |
Forfeiture rate (employees) | 10.00% | 4.00% |
Minimum [Member] | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' |
Risk-free interest rate | 1.00% | 0.60% |
Expected volatility | 113.00% | 131.00% |
Expected term (in years) | '5 years 3 months 18 days | '5 years 2 months 12 days |
Forfeiture rate (officers and directors) | ' | 0.00% |
Maximum [Member] | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' |
Risk-free interest rate | 2.00% | 0.80% |
Expected volatility | 132.00% | 139.00% |
Expected term (in years) | '6 years 1 month 6 days | '6 years 1 month 6 days |
Forfeiture rate (officers and directors) | ' | 4.00% |
Commitments_Additional_Informa
Commitments - Additional Information (Detail) (USD $) | 12 Months Ended | ||
Dec. 31, 2013 | Dec. 31, 2012 | Jul. 31, 2012 | |
sqft | |||
Commitments And Contingencies Disclosure [Abstract] | ' | ' | ' |
Lease office space | 9,300 | ' | ' |
lease valid through | '2015-01 | ' | ' |
exercise option to extend | '2018-10 | ' | ' |
Average rent | $26,677 | ' | ' |
Notice period to exercise option to extend lease | '10 days | ' | ' |
Receive rental income | ' | ' | 3,100 |
Lease expired | '2015 | ' | ' |
Rent expense | $288,000 | $262,000 | ' |
Commitments_Future_Rental_Comm
Commitments - Future Rental Commitments (Detail) (USD $) | Dec. 31, 2013 |
Commitments And Contingencies Disclosure [Abstract] | ' |
2014 | $327,638 |
2015 | 27,365 |
2016 | ' |
2017 | ' |
2018 | ' |
Total | $355,003 |
Income_Taxes_Additional_Inform
Income Taxes - Additional Information (Detail) (USD $) | 12 Months Ended | |
Dec. 31, 2013 | Dec. 31, 2012 | |
Operating Loss Carryforwards [Line Items] | ' | ' |
Provision or benefit for income taxes | ' | ' |
Statutory Federal income tax rate | 34.00% | ' |
Cumulative change in ownership percentage description | 'More than 50% | ' |
Income tax holiday, testing period | '3 years | ' |
Cumulative change in ownership percentage | 50.00% | ' |
Impact on income tax, tax attribute carry forwards | 0 | ' |
R&D tax credit carry forwards | 1,077,789 | 137,123 |
Operating loss expiration year | '2031 | ' |
Uncertain income tax position | 50.00% | ' |
Unrecognized tax benefits | 0 | ' |
Period of change in unrecognized tax benefits | '12 months | ' |
Tax liability, penalties or interest | 0 | 0 |
Federal [Member] | ' | ' |
Operating Loss Carryforwards [Line Items] | ' | ' |
Tax loss carry forwards | 35,500,000 | ' |
R&D tax credit carry forwards | 826,000 | ' |
State and Local Jurisdiction [Member] | CALIFORNIA | ' | ' |
Operating Loss Carryforwards [Line Items] | ' | ' |
Tax loss carry forwards foreign | 16,000,000 | ' |
R&D tax credit carry forwards | $382,000 | ' |
Income_Taxes_Income_Tax_Provis
Income Taxes - Income Tax Provision/(Benefit) (Detail) (USD $) | 12 Months Ended | |
Dec. 31, 2013 | Dec. 31, 2012 | |
Income Tax Disclosure [Abstract] | ' | ' |
Income tax benefit at federal statutory rate | ($7,303,000) | ($5,289,000) |
R & D credit | -804,000 | 279,000 |
Stock options | 207,000 | 205,000 |
Net operating loss adjustment | ' | 14,433,000 |
Other | 37,000 | -20,000 |
Change in federal valuation allowance | 7,863,000 | -9,608,000 |
Total | ' | ' |
Income_Taxes_Significant_Compo
Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Detail) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
Deferred tax assets: | ' | ' |
Accrued expenses | $170,969 | $118,722 |
Stock options expense under ASC 718 | 1,750,192 | 1,362,557 |
Net operating loss carry forwards | 12,993,615 | 6,098,125 |
Income tax credit carry forwards | 1,077,789 | 137,123 |
Property and equipment | 4,542 | 141,755 |
Intangibles | 1,124,264 | 2,288,961 |
Other | 19,946 | 20,110 |
Total deferred tax assets | 17,141,317 | 10,167,353 |
Less: valuation allowance | -17,141,317 | -10,167,353 |
Total deferred tax assets, net of valuation allowance | ' | ' |
Deferred tax liabilities: | ' | ' |
Acquired intangibles | -2,608,755 | -2,608,755 |
Total deferred tax assets/liabilities, net of valuation allowance | ($2,608,755) | ($2,608,755) |
401k_Plan_Additional_Informati
401(k) Plan - Additional Information (Detail) (USD $) | 12 Months Ended | |
Dec. 31, 2013 | Dec. 31, 2012 | |
Compensation And Retirement Disclosure [Abstract] | ' | ' |
Voluntary contributions by employees | 100.00% | ' |
Matching contributions | 100.00% | ' |
Employee contributions | 6.00% | ' |
Total expense incurred in employer matching contribution | $182,416 | $163,171 |
Segment_Information_Additional
Segment Information - Additional Information (Detail) (USD $) | 3 Months Ended | 12 Months Ended | 211 Months Ended | ||||||||
Dec. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Jun. 30, 2012 | Mar. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | |
Segment Reporting [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Recognized revenues | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $2,093,522 |
Summary_of_Quarterly_Financial2
Summary of Quarterly Financial Data (Unaudited) - Quarterly Statements of Operations Data (Detail) (USD $) | 3 Months Ended | 7 Months Ended | 12 Months Ended | 211 Months Ended | |||||||||||||||||||||||
Dec. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Jun. 30, 2012 | Mar. 31, 2012 | Dec. 31, 1996 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2010 | Dec. 31, 2009 | Dec. 31, 2008 | Dec. 31, 2007 | Dec. 31, 2006 | Dec. 31, 2005 | Dec. 31, 2004 | Dec. 31, 2003 | Dec. 31, 2002 | Dec. 31, 2001 | Dec. 31, 2000 | Dec. 31, 1999 | Dec. 31, 1998 | Dec. 31, 1997 | Dec. 31, 2013 | |
Quarterly Financial Information Disclosure [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Revenue | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $2,093,522 |
Loss from operations | -5,722,328 | -5,270,721 | -4,953,239 | -5,592,913 | -4,016,449 | -3,218,499 | -4,221,558 | -4,171,496 | ' | -21,539,201 | -15,628,002 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -201,221,024 |
Net loss | -5,704,715 | -5,253,531 | -4,941,172 | -5,580,867 | -3,996,756 | -3,199,053 | -4,211,163 | -4,152,517 | -259,476 | -21,480,285 | -15,559,489 | -13,259,931 | -8,450,922 | -11,325,058 | -26,647,493 | -22,142,040 | -29,331,773 | -24,782,646 | -6,701,048 | -2,332,077 | -2,105,727 | -16,339,120 | -3,701,084 | -1,055,485 | -1,204,380 | -1,979,400 | -208,657,433 |
Net loss applicable to common stock | ($5,704,715) | ($5,253,531) | ($4,941,172) | ($5,580,867) | ($3,996,756) | ($3,199,053) | ($4,211,163) | ($4,152,517) | ' | ($21,480,285) | ($15,559,489) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ($219,785,356) |
Basic and diluted net loss per share | ($0.06) | ($0.05) | ($0.09) | ($0.12) | ($0.08) | ($0.07) | ($0.09) | ($0.09) | ' | ($0.28) | ($0.33) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Basic and diluted weighted average number of shares of common stock outstanding | 102,710,286 | 102,710,286 | 53,749,791 | 46,265,286 | 47,418,669 | 47,715,709 | 47,715,709 | 47,715,709 | ' | 76,585,752 | 47,641,043 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Subsequent_Events_Additional_I
Subsequent Events - Additional Information (Detail) (USD $) | 1 Months Ended | 12 Months Ended | 211 Months Ended | 0 Months Ended | |||
Jun. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Mar. 24, 2014 | Feb. 27, 2014 | Feb. 10, 2014 | |
Subsequent Event [Member] | Subsequent Event [Member] | Subsequent Event [Member] | |||||
Subsequent Event [Line Items] | ' | ' | ' | ' | ' | ' | ' |
Aggregate unregistered shares of common stock | ' | ' | ' | ' | ' | 1,049,706 | ' |
Agreement holdback period | ' | ' | ' | ' | ' | '6 months | ' |
Additional aggregate unregistered shares of common stock | ' | ' | ' | ' | ' | 4,198,830 | ' |
Total merger consideration | ' | ' | ' | ' | ' | 5,248,536 | ' |
Percent of total merger consideration | ' | ' | ' | ' | ' | 5.00% | ' |
Aggregate gross sales proceeds | ' | ' | ' | ' | ' | ' | $30,000,000 |
Aggregate shares sold and issued | 56,195,000 | ' | ' | ' | 9,847,842 | ' | ' |
Weighted-average sales price | ' | ' | ' | ' | $0.83 | ' | ' |
Aggregate gross proceeds | ' | 28,097,500 | ' | 151,756,371 | 8,200,000 | ' | ' |
Aggregate net proceeds, after sales agent commission and discounts | ' | ' | ' | ' | $8,000,000 | ' | ' |